WO1998035693A2 - Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease - Google Patents
Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease Download PDFInfo
- Publication number
- WO1998035693A2 WO1998035693A2 PCT/IB1998/000781 IB9800781W WO9835693A2 WO 1998035693 A2 WO1998035693 A2 WO 1998035693A2 IB 9800781 W IB9800781 W IB 9800781W WO 9835693 A2 WO9835693 A2 WO 9835693A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- hiap
- cell
- naip
- iap
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Definitions
- the invention relates to the diagnosis and treatment of proliferative disease, in particular, cancer.
- Apoptosis One mechanism by which cells die is referred to as apoptosis, or programmed cell death.
- Apoptosis often occurs as a normal part of the development and maintenance of healthy tissues, and is now known to play a critical role in embryonic development. The failure of a normal apoptotic response has been implicated in the development of cancer; autoimmune disorders, such as lupus erythematosis and multiple sclerosis; and in viral infections, including those associated with herpes virus, poxvirus, and adenovirus.
- Baculoviruses encode proteins termed inhibitors of apoptosis proteins (IAPs) which inhibit the apoptosis that would otherwise occur when insect cells are infected by the baculovirus.
- the baculovirus IAP genes include sequences encoding a ring zinc fmger-like motif (RZF), which is presumed to be directly involved in DNA binding, and two N-terminal domains that consist of a 70 amino acid repeat motif termed a BIR domain (Baculovirus IAP Repeat).
- RZF ring zinc fmger-like motif
- BIR domain Baculovirus IAP Repeat
- IAP and NAIP overexpression are specifically associated with a wide range of cancer types including ovarian cancer, adenocarcinoma, lymphoma, and pancreatic cancer.
- the presence of a fragmented IAP polypeptide in the nucleus, and an overexpression of an IAP polypeptide in the presence of a p53 mutation correlates with a cancer diagnosis, a poor prognosis, and a resistance to numerous chemotherapeutic cancer drugs.
- an therapeutic agent that reduces the biological activity of an IAP polypeptide will induce apoptosis in a cell expressing the polypeptide (e.g. , a cell that is proliferating in a proliferative disease).
- the invention features a method for enhancing apoptosis in a cell from a mammal with a proliferative disease, the method including administering to the cell a compound that inhibits the biological activity of an IAP polypeptide or a NAIP polypeptide, the compound being administered to the cell in an amount sufficient to enhance apoptosis in the cell.
- the cell is proliferating in the proliferative disease.
- the biological activity is the level of expression of the polypeptide (measured, for example, by assaying the amount of polypeptide present in the cell); the level of expression of an mRNA molecule encoding the polypeptide; or an apoptosis-inhibiting activity.
- the polypeptide is selected from the group consisting of HIAP-1, m-HIAP-1, HIAP-2, m-HIAP-2, XIAP, and m-XIAP. In other embodiment, the polypeptide is NAIP, XIAP, HIAP-1, or HIAP-2.
- the mammal is a human or a mouse
- the proliferative disease is cancer, for example, a cancer in a tissue selected from the group consisting of ovary, breast, pancreas, lymph node, skin, blood, lung, brain, kidney, liver, nasopharyngeal cavity, thyroid, central nervous system, prostate, colon, rectum, cervix, endometrium, and lung.
- the compound is a negative regulator of an IAP or an NAIP-dependent anti-apoptotic pathway; a fragment of the IAP polypeptide, the fragment including a ring zinc fmger and having no more than two BIR domains; a nucleic acid molecule encoding a ring zinc finger domain of the IAP polypeptide; a compound that prevents cleavage of the IAP polypeptide or the NAIP polypeptide; a purified antibody or a fragment thereof that specifically binds to the IAP polypeptide or the NAIP polypeptide; a ribozyme; or an antisense nucleic acid molecule have a nucleic acid sequence that is complementary to the coding strand of a nucleic acid sequence encoding the IAP polypeptide or the NAIP polypeptide.
- the cleavage is decreased by at least 20% in the cell; the antibody binds to a BIR domain of the IAP polypeptide or the NAIP polypeptide; the nucleic acid sequence encoding the IAP polypeptide or the NAIP polypeptide has about 50% or greater identity with the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, or the nucleic acid sequence of NAIP; the antisense nucleic acid molecule decreases the level of the nucleic acid sequence encoding the IAP polypeptide or the NAIP polypeptide by at least 20%, the level being measured in the cytoplasm of the cell; the antisense nucleic acid molecule is encoded by a virus vector; or the antisense nucleic acid molecule is encoded by transgene.
- the invention features a method for detecting a proliferative disease or an increased likelihood of the proliferative disease in a mammal that includes: (a) contacting an IAP or a NAIP nucleic acid molecule that is greater than about 18 nucleotides in length with a preparation of nucleic acid from a cell of the mammal, the cell proliferating in the disease, the cell from a tissue; and (b) measuring the amount of nucleic acid from the cell of the mammal that hybridizes to the molecule, an increase in the amount from the cell of the mammal relative to a control indicating a an increased likelihood of the mammal having or developing a proliferative disease.
- the method further includes the steps of: (a) contacting the molecule with a preparation of nucleic acid from the control, wherein the control is a cell from the tissue of a second mammal, the second mammal lacking a proliferative disease; and (b) measuring the amount of nucleic acid from the control, an increase in the amount of the nucleic acid from the cell of the mammal that hybridizes to the molecule relative to the amount of the nucleic acid from the control indicating an increased likelihood of the mammal having or developing a proliferative disease.
- the method further includes the steps of: (a) providing a pair of oligonucleotides having sequence identity to or being complementary to a region of the IAP or the NAIP nucleic acid molecule; (b) combining the pair of oligonucleotides with the nucleic acid under conditions suitable for polymerase chain reaction-mediated nucleic acid amplification; and (c) isolating the amplified nucleic acid or fragment thereof.
- the amplification is carried out using a reverse-transcription polymerase chain reaction (e.g., RACE).
- the method provides measuring the nucleic acid having a nucleotide sequence that has about 50% or greater identity with the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, or the nucleic acid sequence of NAIP. In other embodiments, the method provides measuring the nucleic acid having a nucleotide sequence that has about 50% or greater identity with the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or NAIP.
- the invention features a method for detecting a proliferative disease or an increased likelihood of developing the disease in a mammal, the method including measuring the level of biological activity of an IAP polypeptide or a NAIP polypeptide in a sample of the mammal, an increase in the level of the IAP polypeptide or the NAIP polypeptide relative to a sample from a control mammal being an indication that the mammal has the disease or increased likelihood of developing the disease.
- the sample includes a cell that is proliferating in the disease from the mammal, the cell from a tissue; and the sample from a control mammal is from the tissue, the sample consisting of healthy cells.
- the mammal and the control mammal are the same.
- the biological activity is the level of expression of the polypeptide (measured, for example, by assaying the amount of the polypeptide present in the cell); wherein the biological activity is the level of expression of an mRNA molecule encoding the polypeptide; or wherein the biological activity is an apoptosis-inhibiting activity.
- the polypeptide is selected from the group consisting of HIAP-1, m-HIAP-1, HIAP-2, m-HIAP-2, XIAP, and m-XIAP.
- the polypeptide is NAIP, XIAP, HIAP-1 , or HIAP-2.
- the invention features a method for identifying a compound enhances apoptosis in an affected cell that is proliferating in a proliferative disease that includes exposing a cell that overexpresses an IAP polypeptide or a NAIP polypeptide to a candidate compound, a decrease the level of biological activity of the polypeptide indicating the presence of a compound that enhances apoptosis in the affected cell that is proliferating in the proliferative disease.
- the invention features a method for identifying a compound that enhances apoptosis in an affected cell that is proliferating in a proliferative disease that includes the steps of: (a) providing a cell including a nucleic acid molecule encoding a IAP polypeptide or a nucleic acid molecule encoding a NAIP polypeptide, the nucleic acid molecule being expressed in the cell; and (b) contacting the cell with a candidate compound and monitoring level of biological activity of the IAP polypeptide or the NAIP polypeptide in the cell, a decrease in the level of biological activity of the IAP polypeptide or the NAIP polypeptide in the cell in response to the candidate compound relative to a cell not contacted with the candidate compound indicating the presence of a compound that enhances apoptosis in the affected cell that is proliferating in the proliferative disease.
- the cell further expresses a p53 polypeptide associated with the proliferative disease.
- the biological activity is the level of expression of the polypeptide (measured, for example, by assaying the amount of the polypeptide present in the cell); wherein the biological activity is the level of expression of an mRNA molecule encoding the polypeptide; or wherein the biological activity is an apoptosis-inhibiting activity.
- the polypeptide is selected from the group consisting of HIAP-1, m-HIAP-1, HIAP-2, m-HIAP-2, XIAP, and m-XIAP.
- the polypeptide is NAIP, XIAP, HIAP-1, or HIAP-2.
- the invention features a method for determining the prognosis of a mammal diagnosed with a proliferative disease that includes the steps of: (a) isolating a sample from a tissue from the mammal; and (b) determining whether the sample has an increased an level of biological activity of an IAP polypeptide or an NAIP polypeptide relative to a control sample, an increase in the level in the sample being an indication that the mammal has a poor prognosis.
- the sample includes a cells that is proliferating in the proliferative disease and the control sample is from the tissue, the control sample consisting of healthy cells; and the sample and the control sample are from the mammal.
- the sample further includes a cell expressing a p53 polypeptide associated with the proliferative disease.
- the biological activity is the level of expression of the polypeptide (measured, for example, by assaying the amount of the polypeptide present in the cell); wherein the biological activity is the level of expression of an mRNA molecule encoding the polypeptide; or wherein the biological activity is an apoptosis-inhibiting activity.
- the polypeptide is selected from the group consisting of HIAP-1, m-HIAP-1, HIAP-2, m-HIAP-2, XIAP, and m-XIAP.
- the polypeptide is NAIP, XIAP, HIAP-1, or HIAP-2.
- the level is assayed by measuring the amount of IAP peptide of less than 64 kDa present in the sample.
- the invention features a method for determining the prognosis of a mammal diagnosed with a proliferative disease that includes the steps of: (a) isolating a sample from the mammal, the sample having a nuclear fraction; and (b) measuring the amount of a polypeptide that is recognized by an antibody that specifically binds an IAP polypeptide or an antibody that specifically binds an NAIP polypeptide in the nuclear fraction of the sample relative an amount from a control sample, an increase in the amount from the sample being an indication that the mammal has a poor prognosis.
- the sample is from a tissue of the mammal, the sample including a cell that is proliferating in the proliferative disease, and the control sample is from the tissue, the control sample consisting of healthy cells.
- the sample and the control sample are from the mammal.
- the biological activity is the level of expression of the polypeptide (measured, for example, by assaying the amount of the polypeptide present in the cell); wherein the biological activity is the level of expression of an mRNA molecule encoding the polypeptide; or wherein the biological activity is an apoptosis-inhibiting activity.
- the polypeptide is selected from the group consisting of HIAP-1, m-HIAP-1, HIAP-2, m-HIAP-2, XIAP, and m-XIAP.
- the polypeptide is NAIP, XIAP, HIAP-1, or HIAP-2.
- the amount is measured by immunological methods.
- the invention features a method for treating a mammal diagnosed as having a proliferative disease that includes the steps of: (a) measuring the amount of an IAP or NAIP polypeptide in a first sample from a tissue from the mammal, the first sample including a cell that is proliferating in the proliferative disease; (b) measuring the amount of the polypeptide in a second sample from the tissue, the second sample consisting of healthy cells; (c) detecting an increase in the amount of the polypeptide in the first sample to the amount of the polypeptide in the second sample; and (d) treating the mammal with a compound that decreases the biological activity of the polypeptide.
- the first sample and the second sample are from the mammal.
- the biological activity is the level of expression of the polypeptide (measured, for example, by assaying the amount of the polypeptide present in the cell); wherein the biological activity is the level of expression of an mRNA molecule encoding the polypeptide; or wherein the biological activity is an apoptosis-inhibiting activity.
- the polypeptide is selected from the group consisting of HIAP-1, m-HIAP-1, HIAP-2, m-HIAP-2, XIAP, and m-XIAP.
- the polypeptide is NAIP, XIAP, HIAP-1 , or HIAP-2.
- the invention features the use of a compound that decreases the biological activity an IAP polypeptide or a NAIP polypeptide for the manufacture of a medicament for the enhancement of apoptosis.
- the biological activity is the level of expression of the polypeptide (measured, for example, by assaying the amount of the polypeptide present in the cell); wherein the biological activity is the level of expression of an mRNA molecule encoding the polypeptide; or wherein the biological activity is an apoptosis-inhibiting activity.
- the polypeptide is selected from the group consisting of HIAP-1, m-HIAP-1, HIAP-2, m-HIAP-2, XIAP, and m-XIAP.
- the polypeptide is NAIP, XIAP, HIAP-1 , or HIAP-2.
- the invention features a kit for diagnosing a mammal for the presence of a proliferative disease or an increased likelihood of developing a proliferative disease, the kit compromising an oligonucleotide that hybridizes to a nucleic acid sequence that encodes an IAP polypeptide or a NAIP polypeptide.
- the biological activity is the level of expression of the polypeptide (measured, for example, by assaying the amount of the polypeptide present in the cell); wherein the biological activity is the level of expression of an mRNA molecule encoding the polypeptide; or wherein the biological activity is an apoptosis-inhibiting activity.
- the polypeptide is selected from the group consisting of HIAP-1, m-HIAP-1, HIAP-2, m-HIAP-2, XIAP, and m-XIAP.
- the polypeptide is NAIP, XIAP, HIAP-1, or HIAP-2.
- the invention features a transgenic mammal, the mammal having an elevated level of biological activity of an IAP polypeptide or a NAIP polypeptide
- the biological activity is the level of expression of the polypeptide (measured, for example, by assaying the amount of the polypeptide present in the cell), wherein the biological activity is the level of expression of an mRNA molecule encoding the polypeptide, or wherein the biological activity is an apoptosis-inhibiting activity
- the polypeptide is selected from the group consisting of HIAP-1, m-HIAP-1, HIAP-2, m-HIAP-2, XIAP, and m-XIAP
- the polypeptide is NAIP, XIAP, HIAP-1 , or HIAP-2
- IAP gene is meant a gene encoding a polypeptide having at least one BIR domain and is capable of modulating (inhibiting or enhancing) apoptosis m a cell or tissue when provided by other mtracellular or extracellular delivery methods (see, e g , the U S S N s 08/511,485, 08/576,965, and PCT/1B96/01022)
- the IAP gene is a gene having about 50% or greater nucleotide sequence identity to at least one ofthe IAP amino acid encoding sequences of Figs 1-6 (SEQ ID NO 3, SEQ ID NO 5, SEQ ID NO 7, SEQ ID NO 9, SEQ ID NO 11 , and SEQ ID NO 13) or portions thereof, or has a ring zinc fmger domain
- the region of sequence over which identity is measured is a region encoding at least one BIR domain and a ring zinc fmger domain
- Mammalian IAP genes include nucleotide sequences isolated from any
- a virus vector is meant a functional or attenuated virus that is capable of delivering to a virus-infected cell a nucleic acid molecule
- the virus vector has been genetically engineered according to standard molecular biology techniques to bear a heterologous nucleic acid molecule.
- Virus vectors include, without limitation, adenoviruses, retroviruses, baculoviruses, cytomegaloviruses (CMV), and vaccinia viruses.
- IAP protein or “IAP polypeptide” is meant a polypeptide, or fragment thereof, encoded by an IAP gene.
- NAIP gene and “NAIP polypeptide” is meant the NAIP genes, fragments thereof, and polypeptides encoded by the same described in UK9601108.5 filed January 19, 1996 and PCT Application No. PCT/IB97/00142 (claiming priority from UK9601108.5) filed January 17, 1997.
- BIR domain is meant a domain having the amino acid sequence ofthe consensus sequence: Xaal-Xaal-Xaal-Arg-Leu-Xaal-Thr-Phe-Xaal-Xaal-Trp-Pro-Xaa2-Xaal- Xaal-Xaa2-Xaa2-Xaal-Xaal-Xaal-Xaal-Leu-Ala-Xaal-Ala-Gly-Phe-Tyr-Tyr-Xaal-Gly-Xaal- Xaal-Asp-Xaal-Val-Xaal-Cys-Phe-Xaal-Cys-Xaal-Xaal- Xaal-Xaal-Trp-Xaal- Xaal-Xaal-Asp-Xaal-Xaal-Xaal-Asp-Xaal-Xaal-Xaal-Xaal-His-Xaal-Xaal-Xaal-X
- ring zinc finger or “RZF” is meant a domain having the amino acid sequence of the consensus sequence: Glu-Xaal-Xaal-Xaal-Xaal-Xaal-Xaal-Xaal-Xaa2-Xaal-Xaal-Xaal-Cys- Lys-Xaa3-Cys-Met-Xaal-Xaal-Xaal-Xaal-Xaal-Xaa3-Xaal-Phe-Xaal-Pro-Cys-Gly-His-Xaal- Xaal-Xaal-Cys-Xaal-Xaal-Cys-Ala- Xaal-Xaal-Xaal-Xaal-Cys-Pro-Xaal-Cys, wherein Xaal is any amino acid, Xaa2 is Glu or Asp, and Xaa3 is Val or He (SEQ ID NO:l).
- the sequence is substantially identical to the RZF domains provided herein for the human or murine XIAP, HIAP-1, or HIAP-2.
- enhancing apoptosis is meant increasing the number of cells which apoptose in a given cell population.
- the cell population is selected from a group including ovarian cancer cells, breast cancer cells, pancreatic cancer cells, T cells, neuronal cells, fibroblasts, or any other cell line known to proliferate in a laboratory setting.
- the degree of apoptosis enhancement provided by an apoptosis enhancing compound in a given assay will vary, but that one skilled in the art can determine the statistically significant change in the level of apoptosis which identifies a compound which enhances apoptosis otherwise limited by an IAP.
- enhancing apoptosis means that the increase in the number of cells undergoing apoptosis is at least 25%, more preferably the increase is 50%, and most preferably the increase is at least one-fold.
- the sample monitored is a sample of cells which normally undergo insufficient apoptosis (i.e., cancer cells).
- proliferative disease is meant a disease which is caused by or results in inappropriately high levels of cell division, inappropriately low levels of apoptosis, or both.
- cancers such as lymphoma, leukemia, melanoma, ovarian cancer, breast cancer, pancreatic cancer, and lung cancer are all examples of proliferative disease.
- a neoplasm i.e., any abnormal proliferation of cells, malignant or benign
- a “cell proliferating in a proliferative disease” is meant a cell whose abnormal proliferation contributes to the disease.
- the cell expresses the antigen PCNA.
- polypeptide is meant any chain of more than two amino acids, regardless of post-translational modification such as glycosylation or phosphorylation.
- IAP or NAIP biological activity is meant any activity known to be caused in vivo or in vitro by a NAIP or an IAP polypeptide.
- IAP and NAIP polypeptides are those described herein, and include, without limitation, a level of expression ofthe polypeptide that is normal for that cell type, a level of expression of the mRNA that is normal for that cell type, an ability to block apoptosis, and an ability to be cleaved.
- a “compound that decreases the biological activity” is meant a compound that decreases any activity known to be caused in vivo or in vitro by a NAIP polypeptide or an IAP polypeptide.
- Preferred compounds include, without limitation, an antisense nucleic acid molecule that is complementary to the coding strand of nucleic acid molecule that encodes an IAP or a NAIP polypeptide; an antibody, such as a neutralizing antibody, that specifically binds to an IAP or a NAIP polypeptide; and a negative regulator of an IAP or a NAIP polypeptide, such as a polypeptide fragment that includes the ring zing fmger of an IAP polypeptide, a polypeptide fragment that has no more than two BIR domains, or nucleic acid molecules encoding these polypeptide fragments.
- substantially identical is meant a polypeptide or nucleic acid exhibiting at least
- the length of comparison sequences will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids.
- the length of comparison sequences will generally be at least 50 nucleotides, preferably at 5 least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 1 10 nucleotides.
- Sequence identity is typically measured using sequence analysis software with the default parameters specified therein (e.g., Sequence Analysis Software Package ofthe Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University
- Conservative substitutions typically include substitutions within the following groups: glycine, alanine, valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.
- substantially pure polypeptide is meant a polypeptide that has been separated from the components that naturally accompany it.
- the polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated.
- the polypeptide is an IAP polypeptide that is at least 75%, more preferably at least 90%, and most preferably at least
- a substantially pure IAP polypeptide may be obtained, for example, by extraction from a natural source (e.g. a fibroblast, neuronal cell, or lymphocyte) by expression of a recombinant nucleic acid encoding an IAP polypeptide, or by chemically synthesizing the protein. Purity can be measured by any appropriate method, e.g., by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
- a natural source e.g. a fibroblast, neuronal cell, or lymphocyte
- Purity can be measured by any appropriate method, e.g., by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
- substantially pure polypeptides include those derived from eukaryotic
- substantially pure DNA DNA that is free ofthe genes which, in the naturally-occurring genome of the organism from which the DNA ofthe invention is derived, flank the gene.
- the term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence.
- transformed cell is meant a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a DNA molecule encoding (as used herein) an IAP polypeptide.
- transgene any piece of DNA which is inserted by artifice into a cell, and becomes part of the genome ofthe organism which develops from that cell.
- a transgene may include a gene which is partly or entirely heterologous (i.e., foreign) to the transgenic organism, or may represent a gene homologous to an endogenous gene of the organism.
- transgenic any cell which includes a DNA sequence which is inserted by artifice into a cell and becomes part of the genome ofthe organism which develops from that cell.
- the transgenic organisms are generally transgenic mammalian (e.g., rodents such as rats or mice) and the DNA (transgene) is inserted by artifice into the nuclear genome.
- transformation is meant any method for introducing foreign molecules into a cell. Lipofection, calcium phosphate precipitation, retroviral delivery, electroporation, and biolistic transformation are just a few of the teachings which may be used.
- biolistic transformation is a method for introducing foreign molecules into a cell using velocity driven microprojectiles such as tungsten or gold particles. Such velocity-driven methods originate from pressure bursts which include, but are not limited to, helium-driven, air-driven, and gunpowder-driven techniques.
- Biolistic transformation may be applied to the transformation or transfection of a wide variety of cell types and intact tissues including, without limitation, intracellular organelles (e.g., and mitochondria and chloroplasts), bacteria, yeast, fungi, algae, animal tissue, and cultured cells.
- positioned for expression is meant that the DNA molecule is positioned adjacent to a DNA sequence which directs transcription and translation of the sequence (i.e., facilitates the production of, e.g., an IAP polypeptide, a recombinant protein or a RNA molecule).
- reporter gene is meant a gene whose expression may be assayed; such genes include, without limitation, glucuronidase (GUS), luciferase, chloramphenicol transacetylase (CAT), and ⁇ -galactosidase.
- GUS glucuronidase
- CAT chloramphenicol transacetylase
- ⁇ -galactosidase glucuronidase
- promoter minimal sequence sufficient to direct transcription. Also included in the invention are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for cell type-specific, tissue-specific or inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the native gene.
- operably linked is meant that a gene and one or more regulatory sequences are connected in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins are bound to the regulatory sequences).
- conserved region is meant any stretch of six or more contiguous amino acids exhibiting at least 30%, preferably 50%, and most preferably 70% amino acid sequence identity between two or more ofthe IAP family members, (e.g., between human HIAP-1, HIAP-2, and XIAP). Examples of preferred conserved regions are shown (as boxed or designated sequences) in Figures 5-7 and Tables 1 and 2, and include, without limitation, BIR domains and ring zinc finger domains.
- detectably-labelled any means for marking and identifying the presence of a molecule, e.g., an oligonucleotide probe or primer, a gene or fragment thereof, or a cDNA molecule.
- Methods for detectably-labelling a molecule are well known in the art and include, without limitation, radioactive labelling (e.g. , with an isotope such as 32 P or 35 S) and nonradioactive labelling (e.g., chemiluminescent labelling, e.g., fluorescein labelling).
- antisense as used herein in reference to nucleic acids, is meant a nucleic acid sequence, regardless of length, that is complementary to a region on the coding strand of nucleic acid molecule (e.g., genomic DNA, cDNA, or mRNA) that encodes an IAP or a NAIP polypeptide.
- the region ofthe nucleic acid molecule encoding an IAP or a NAIP polypeptide that the antisense molecule is complementary to may be a region within the coding region, a region upstream ofthe coding region, a region downstream ofthe coding region, or a region within an intron, where the nucleic acid molecule is genomic DNA.
- the antisense nucleic acid is capable of enhancing apoptosis when present in a cell which normally does not undergo sufficient apoptosis and/or is between 8 and 25 nucleotides in length.
- the increase is at least 10%, relative to a control, more preferably 25%, and most preferably 1-fold or more. It will be understood that antisense nucleic acid molecules may have chemical modifications known in the art of antisense design to enhance antisense compound efficiency.
- purified antibody is meant antibody which is at least 60%, by weight, free from proteins and naturally occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably 90%, and most preferably at least 99%, by weight, antibody, e.g., an IAP specific antibody.
- a purified antibody may be obtained, for example, by affinity chromatography using recombinantly-produced protein or conserved motif peptides and standard techniques.
- telomere binding By “specifically binds” is meant an antibody that recognizes and binds a protein but that does not substantially recognize and bind other molecules in a sample, e.g., a biological sample, that naturally includes protein.
- Fig. 1 is the human XIAP cDNA sequence (SEQ ID NO: 3) and the XIAP polypeptide sequence (SEQ ID NO: 4).
- Fig. 2 is the human HIAP-1 cDNA sequence (SEQ ID NO: 5) and the HIAP-1 polypeptide sequence (SEQ ID NO: 6).
- Fig. 3 is the human HIAP-2 cDNA sequence (SEQ ID NO: 7) and the HIAP-2 polypeptide sequence (SEQ ID NO: 8).
- Fig. 4 is the murine XIAP (also referred to as “MIAP-3” or “m-XIAP”) cDNA sequence (SEQ ID NO: 9) and encoded murine XIAP polypeptide sequence (SEQ ID NO: 10).
- Fig. 5 is the murine HIAP-1 (also referred to as “MIAP-1” or “m-HIAP-1”) cDNA sequence (SEQ ID NO: 11) and the encoded murine HIAP-1 polypeptide sequence (SEQ ID NO: 12).
- Fig. 6 is the murine HIAP-2 (also referred to as “MIAP-2”or “m-HIAP-2") cDNA sequence (SEQ ID NO: 13) and the encoded murine HIAP-2 polypeptide (SEQ ID NO: 14).
- Fig. 7 is a photograph of a Northern blot illustrating human HIAP-1 and HIAP-2 mRNA expression in human tissues.
- Fig. 8 is a photograph of a Northern blot illustrating human HIAP-2 mRNA expression in human tissues.
- Fig. 9 is a photograph of a Northern blot illustrating human XIAP mRNA expression in human tissues.
- Figs. 10A - 10D are graphs depicting suppression of apoptosis by XIAP, HIAP-1, HIAP-2, BCL-2, SMN, and 6-MYC.
- Fig. 11 is a photograph of an agarose gel containing cDNA fragments that were amplified, with HIAP 1 -specific primers, from RNA obtained from Raji, Ramos, EB-3, Burkitt' s lymphoma cells, and Jiyoye cells, and cells from normal placenta.
- Fig. 12 is a photograph of a Western blot containing protein extracted from Jurkat and astrocytoma cells stained with an anti-XIAP antibody. The position and size of a series of marker proteins is indicated.
- Fig. 13 is a photograph of a Western blot containing protein extracted from Jurkat cells following treatment as described in Example XII. The blot was stained with a rabbit polyclonal anti-XIAP antibody. Lane 1, negative control; lane 2, anti-Fas antibody; lane 3, anti-Fas antibody and cycloheximide; lane 4, TNF- ⁇ ; lane 5, TNF- and cycloheximide.
- Fig. 12 is a photograph of a Western blot containing protein extracted from Jurkat and astrocytoma cells stained with an anti-XIAP antibody. The position and size of a series of marker proteins is indicated.
- Fig. 13 is a photograph of a Western blot containing protein extracted from Jurkat cells following treatment as described in Example
- FIG. 14 is a photograph of a Western blot containing protein extracted from HeLa cells following exposure to anti-Fas antibodies. The blot was stained with a rabbit polyclonal anti-XIAP antibody. Lane 1, negative control; lane 2, cycloheximide; lane 3, anti-Fas antibody; lane 4, anti-Fas antibody and cycloheximide; lane 5, TNF- ⁇ ; lane 6, TNF- ⁇ and cycloheximide.
- Figs. 15A and 15B are photographs of Western blots stained with rabbit polyclonal anti-XIAP antibody. Protein was extracted from HeLa cells (Fig. 15 A) and Jurkat cells (Fig. 15B) immediately, 1, 2, 3, 5, 10, and 22 hours after exposure to anti-Fas antibody.
- Figs. 16A and 16B are photographs of Western blots stained with an anti-CPP32 antibody (Fig. 16A) or a rabbit polyclonal anti-XIAP antibody (Fig. 16B). Protein was extracted from Jurkat cells immediately, 3 hours, or 7 hours after exposure to an anti-Fas antibody. In addition to total protein, cytoplasmic and nuclear extracts are shown.
- Fig. 17 is a photograph of a polyacrylamide gel following electrophoresis ofthe products of an in vitro XIAP cleavage assay.
- Figs. 18 and 19 shows the increased level of HIAP-1 and HIAP-2 mRNA, respectively, in breast cancer cell lines having p53 mutations (lanes 5-7). The bottom portion of the figure shows the control.
- Fig. 20 shows the influence of Taxol on DNA fragmentation in Cisplatin-sensitive
- Fig. 21 shows the influence of Cisplatin on DNA fragmentation in sensitive (right) and resistant (left) human ovarian epithelial cancer cells.
- Fig. 22 shows the effects of Taxol on XIAP and HIAP-2 protein levels in Cisplatin sensitive (right) and resistant (left) human ovarian epithelial cancer cells.
- Figs. 23 A and 23B show the influence of Taxol and TGF ⁇ on HIAP-2 mRNA levels in Cisplatin sensitive (right) and resistant (left) human epithelial cancer cells.
- Figs. 24A and 24B show the effect of TGF ⁇ on XIAP protein expression (Fig. 24A) and DNA fragmentation (Fig. 24B) in Cisplatin-sensitive (OV2008) and cisplatin-resistant (C13) cells.
- Fig. 25 is a series of bar graphs showing the effect of XIAP and HIAP-2 down- regulation on ovarian epithelial cancer cell viability and number.
- the top two panels show dead cells as a percentage of total cell population.
- the bottom two panels illustrate total cell number at the end of the infection period.
- Data represents the mean +/- SEM of four experiments. **p ⁇ 0.01, ***p ⁇ 0.001 (compared to vector control).
- Fig. 26A is a set of photographs showing the influence of XIAP down-regulation on whole cell morphology (phase contrast; black arrows indicate cell detachment) in OV2008 cells after 60 hours of adenovirus infection with vector only (left) or adenoviral antisense XIAP (right).
- MOI 5 (IX; "a” and "b”); magnification 400X.
- 26B is a series of photographs ("a” through “d”) showing the influence of XIAP down-regulation on nuclear morphology (Hoechst staining; white arrows show nuclear fragmentation) in OV2008 cells after 60 hours of adenovirus infection with vector only ("a” and “c") or adenoviral antisense XIAP ("b” and “d”).
- Fig. 27 A is a series of photographs showing effects of cisplatin-induced apoptosis (at 0 and 30 ⁇ M cisplatin in a 24 hour culture) the nuclear morphology of cisplatin-sensitive cells (OV2008; left two photographs) and cisplatin-resistant cells (C13; right two photographs), using Hoechst staining, magnification 400X; arrows show fragmented nuclei.
- Fig. 27B is a set of photographs showing agarose gel immobilized electrophoretically resolved apoptotic low molecular weight DNA fragmentation from cisplatin treated OV2008 and C13 cells.
- Fig. 27C is a line graph showing a concentration-response study of apoptosis in OV2008 and C13 cells following 24 hours of culture in 0, 10, 20, and 30 ⁇ M cisplatin. Data represents the mean +/- SEM of three experiments. **p ⁇ 0.01 (compared to control).
- Fig. 28 A is a series of representative Western blotting analyses showing concentration-dependent inhibition of XIAP and HIAP-2 protein expression in cisplatin- sensitive (OV2008) and cisplatin-resistant (C13) ovarian epithelial cancer cells following 24 hour culture with 0, 10, 20, and 30 ⁇ M cisplatin. Equal amounts of solubilized proteins (20- 60 ⁇ g/lane, depending on the individual experiment) were analyzed by Western blot using anti -human XIAP or anti-HIAP-2 antibodies.
- Fig. 28B is a panel of bar graphs showing the changes in XIAP (left two graphs) and HIAP-2 (right two graphs) protein content as analyzed densitometrically, using the Molecular Dynamics Phosphoimager, for cisplatin-treated (24 hours at indicated concentration) OV2008 cells (upper two graphs) and C13 cells (lower two graphs). Data represents the mean +/- SEM of three experiments. *p ⁇ 0.05, **p ⁇ 0.01 (compared to control).
- Fig. 29 A is a series of representative Western blotting analyses showing concentration-dependent inhibition of XIAP and HIAP-2 protein expression in cisplatin- sensitive (OV2008) and cisplatin-resistant (C13) ovarian epithelial cancer cells following 6, 12, or 24 hours of culture with or without 30 ⁇ M cisplatin. Equal amounts of solubilized proteins (20-60 ⁇ g/lane, depending on the individual experiment) were analyzed by Western blot using anti-human XIAP or anti-HIAP-2 antibodies.
- Fig. 29B is a panel of bar graphs showing the changes in XIAP (left two graphs) and
- HIAP-2 (right two graphs) protein content as analyzed densitometrically, using the Molecular Dynamics Phosphoimager, for OV2008 cells (white bars) and C13 cells (black bars) cultured with or without 30 ⁇ M cisplatin for 6, 12, or 24 hours. Data represents the mean +/- SEM of three experiments. *p ⁇ 0.05, **p ⁇ 0.01 (compared to control).
- Fig. 30A is a series of representative Western blotting analyses showing concentration-dependent inhibition of XIAP and HIAP-2 protein expression in cisplatin- sensitive (A2780s) and cisplatin-resistant (A2780cp) ovarian epithelial cancer cells following hours of culture with or without 30 ⁇ M cisplatin. Equal amounts of solubilized proteins (40- 60 ⁇ g/lane, depending on the individual experiment) were analyzed by Western blot using anti-human XIAP or anti-HIAP-2 antibodies.
- Fig. 30B is a panel of bar graphs showing the changes in XIAP (top graph) and HIAP-2 (bottom graph) protein content as analyzed densitometrically, using the Molecular Dynamics Phosphoimager, for A2780s cells (left) and A2780cp cells (right) cultured with (black bars) or without (white bars) 30 ⁇ M cisplatin for 24 hours. Data represents the mean +/- SEM of three experiments. **p ⁇ 0.01 (compared to control). Fig.
- 31 A is set of photographs ("a” through “d") showing the effects of XIAP overexpression on the apoptotic action of cisplatin (30 ⁇ M) on nuclear morphology of cisplatin-sensitive OV2008 cells after 48 hours of infection of these cells with adenoviral sense XIAP cDNA or vector only (control).
- a vector (no cisplatin);
- b sense XIAP (no cisplatin);
- c vector plus cisplatin-treatment;
- d sense XIAP plus cisplatin treatment.
- Fig. 3 IB is a graph showing the percentage of total cell population undergoing apoptosis of 30 ⁇ M cisplatin-treated OV2008 cells following 48 hours of infection of these cells with adenoviral sense XIAP cDNA or vector only (control). Data represent mean +/- SEM of three experiments. *p ⁇ 0.05, ***p ⁇ 0.001 (compared to vector control); * pO.Ol, ⁇ "" p ⁇ 0.001 (compared to vector plus cisplatin group).
- Fig. 31C is a representative Western blotting analysis showing changes in XIAP protein content in OV2008 cells following infection with adenoviral sense XIAP cDNA or vector only (control) with or without treatment with 30 ⁇ M cisplatin. Lanes are, from left to right: control, vector, vector plus cisplatin, sense XIAP, and sense XIAP plus cisplatin.
- Fig. 3 ID is a graph showing the changes in XIAP protein content in OV2008 cells following infection with adenoviral sense XIAP cDNA or vector only (control) with or without treatment with 30 ⁇ M cisplatin, as analyzed densitometrically, using the Molecular Dynamic Phosphoimager. Data represent mean +/- SEM of three experiments. * p ⁇ 0.05, " * p ⁇ 0.001 (compared to vector control); TM p ⁇ 0.01, ⁇ * p ⁇ 0.001 (compared to vector + cisplatin group).
- Figs. 32A-32D are a series of photographs showing the in situ detection of apoptosis (using TUNEL) and immunolocalization of PCNA, XIAP and HIAP-2 in human ovarian surface epithelial tumour tissue.
- Fig. 32A indicates the in situ TUNEL localization of apoptotic cells.
- Figs. 32B, 32C, and 32D represent immuno-reactivates for PCNA, XIAP and HIAP-2, respectively.
- the regions of tumor shown in the circle and the rectangle in each of Figs. 32A-32D was TUNEL -positive and TUNEL-negative, respectively. Magnification is 400X.
- Ovarian Carcinoma Ovarian Carcinoma. mRNA in situ analysis suggest a role for NAIP in the developmental biology of the ovary. Overexpression of HIAP-2 and XIAP mRNA has also been documented in some ovarian cancer cell lines.
- pancreatic cancer cell lines tested to date demonstrate HIAP-1 and HIAP-2 mRNA elevation.
- wild- type p53 also transcriptionally suppresses HIAP-1 and HIAP-2.
- DNA damage that includes the increase in wild-type levels p53 levels would therefore result in decreased HIAP-1 and HIAP-2 in normal cells, resulting in apoptosis. Mutations in the p53 gene would therefore result in a loss of transcriptional control of these IAP genes.
- p53 mutant cancer cells would display constitutively high levels of HIAP- 1 and HIAP-2, rendering the cells resistant to anti-cancer therapies.
- the p53/HIAP-l and HIAP-2 correlations may be extended to the other cancer cell line panels.
- One may directly demonstrate p53 regulation of the IAPs using transfection assays and northern blot analysis.
- mice have constructed a number of IAP and NAIP transgenic mouse expression vectors, including T-cell, B-cell, and neuronal specific promoter constructs. Founder mice have been identified and are viable, and, for most of these constructs, we have developed breeding colonies. These mice will likely be prone to cancers ofthe tissue types in which the promoter is active. Thus the mice provide an excellent resource for testing the efficacy of anti-sense oligonucleotides and for screening for apoptosis-enhancing cancer therapeutics. Standard mouse drug screening models and gene delivery protocols may be employed to utilize the mice for this purpose.
- Mutation ofthe p53 gene remains one ofthe best prognostic indicators in cancer biology. However, the number of different mutations identified to date is great and the mutations are scattered throughout the gene. In addition, many mutations in p53 result in an inappropriate stabilization of the protein, which allows detection at the protein level rather than at the mRNA level. Mutations which alter the transactivation/repression activities ofthe protein are not necessarily apparent at either the mRNA or protein levels.
- IAP and NAIP expression levels correlate with p53 mutation they may provide more valuable prognostic information and assist in the determination of which patients require more aggressive treatment or which patients are, perhaps, not treatable with currently approved therapies.
- This latter class of patients may be identified as ideal candidates for clinical testing of new cancer therapeutics, particularly those which decrease IAP levels or act in a manner independent of the anti-apoptotic pathway.
- the invention provides at least two assays for prognosis an diagnosis.
- Semi- quantitative RT-PCR based assays may be used to assay for IAP and/or NAIP gene or protein expression levels.
- monoclonal antibodies may be incorporated into an ELISA (enzyme-linked immunosorbent assay) -type assay for direct determination of protein levels.
- antisense constructs which enhance apoptosis at least 10%, preferably by enhancing degradation of the RNA in the nucleus.
- the invention features small molecule screening assays which may be used to identify lead compounds that negatively regulate the IAPs or NAIP. For example, compounds which enhance apoptosis in the presence of IAP overexpression or which decrease the level of IAP biological activity may be detected and are useful cancer therapeutics.
- Molecules that are found, by the methods described herein, to effectively modulate IAP gene expression or polypeptide activity may be tested further in standard animal cancer models. If they continue to function successfully in an in vivo setting, they may be used as therapeutics to either inhibit or enhance apoptosis, as appropriate.
- Retroviral vectors may be used as an oligonucleotide transfer delivery system for a therapeutic constructs.
- Standard non-viral delivery methods may be used.
- Numerous vectors useful for viral delivery are generally known (Miller, A.D., Human Gene Therapy 1 : 5-14, 1990; Friedman, T., Science 244: 1275-1281, 1989; Eglitis and Anderson, BioTechmques 6: 608-614, 1988; Tolstoshev and Anderson, Curr. Opin. Biotech. 1 : 55-61, 1990; Cornetta et al, Prog. Nucl. Acid Res. and Mol. Biol. 36: 311-322, 1987; Anderson, W. F., Science 226: 401-409, 1984; Moen, R.
- Retroviral vectors are particularly well developed and have been used in clinical settings (Rosenberg et al, New Engl. J. Med. 323: 570-578, 1990; Anderson et al, U.S. 5 Patent No. 5,399,346).
- Non-viral approaches may also be employed for the introduction of therapeutic nucleic acid molecules (e.g., oligonucleotides) into cells otherwise predicted to undergo apoptosis.
- IAP may be introduced into a neuron or a T cell by lipofection (Feigner et al, Proc. Natl. Acad. Sci. USA 84: 7413-7417, 1987; Ono et al, Neurosci. Lett. 10 1 17: 259-263, 1990; Brigham et al, Am. J. Med. Sci. 298: 278-281, 1989; Staubinger et al, Meth. Enz.
- the therapeutic nucleic acid construct is preferably applied to the site ofthe needed apoptosis event (for example, by injection).
- nucleic acid expression can be directed from any suitable 20 promoter (e.g., the human cytomegalovirus (CMV), simian virus 40 (SV40), or metallothionein promoters), and regulated by any appropriate mammalian regulatory element.
- CMV human cytomegalovirus
- SV40 simian virus 40
- metallothionein promoters e.g., metallothionein promoters
- enhancers known to preferentially direct gene expression in ovarian cells, breast tissue, neural cells, T cells, or B cells may be used to direct expression.
- the enhancers used could include, without limitation, those that are characterized as tissue- 25 or cell-specific in their expression.
- regulation may be mediated by the cognate regulatory sequences or, if desired, by regulatory sequences derived from a heterologous source, including any ofthe promoters or regulatory elements described above.
- Anti-cancer therapy is also accomplished by direct administration ofthe therapeutic 30 sense IAP nucleic acid or antisense IAP nucleic acid (e.g., oligonucleotides) to a cell that is expected to require enhanced apoptosis.
- the nucleic acid molecule may be produced and isolated by any standard technique, but is most readily produced by in vitro transcription using an IAP related nucleic acid under the control of a high efficiency promoter (e.g., the T7 promoter), or, by organic synthesis techniques (for, e.g., oligonucleotides).
- Administration of IAP antisense nucleic acid to malignant cells can be carried out by any of the methods for direct nucleic acid administration described above, or any method otherwise known in the art.
- Another therapeutic approach within the invention involves administration of recombinant IAP protein fragments or IAP antibodies, either directly to the site where enhanced apoptosis is desirable (for example, by injection) or systemically (for example, by any conventional recombinant protein administration technique).
- NAIP or an IAP protein a polypeptide fragment thereof, a mutant thereof, or antibodies that specifically bind NAIP or an IAP polypeptide depends on a number of factors, including the size and health of the individual patient, but, generally, between 0.1 mg and 500 mg inclusive are administered per day to an adult in any pharmaceutically acceptable formulation.
- An IAP or NAIP mutant protein or protein fragment, a nucleic acid molecule encoding the same, a nucleic acid molecule encoding an IAP or NAIP antisense nucleic acid, or a inhibitor of an IAPs or NAIP may be administered within a pharmaceutically-acceptable diluent, carrier, or excipient, in unit dosage form.
- Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer the compounds to patients suffering from a disease that is caused by excessive cell proliferation. Administration may begin before the patient is symptomatic.
- administration may be parenteral, intravenous, intraarterial, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intrathecal, intracapsular, intracisternal, intraperitoneal, intranasal, aerosol, suppository, or oral administration.
- therapeutic formulations may be in the form of liquid solutions or suspensions; for oral administration, formulations may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders, nasal drops, or aerosols.
- Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes.
- Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds.
- parenteral delivery systems for IAP or NAIP modulatory compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
- Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.
- treatment with an IAP or NAIP mutant proteins or IAP or NAIP fragments, related genes, or other modulatory compounds may be combined with more traditional therapies for the proliferative disease such as surgery or chemotherapy.
- IAP and NAIP polypeptides and nucleic acid sequences find diagnostic use in the detection or monitoring of conditions involving insufficient levels of apoptosis, i.e., proliferative disease.
- proliferative disease i.e., proliferative disease.
- increased expression of IAPs or NAIP, alterations in localization, and IAP or NAIP cleavage correlate with inhibition of apoptosis and cancer in humans.
- an increase in the level of IAP or NAIP production may provide an indication of a proliferative condition or a predisposition to such a condition.
- Levels of IAP or NAIP expression may be assayed by any standard technique.
- IAP or NAIP expression in a biological sample may be monitored by standard Northern blot analysis or may be aided by PCR (see, e.g., Ausubel et al, Current Protocols in Molecular Biology. John Wiley & Sons, New York, 1994; PCR Technology: Principles and Applications for DNA Amplification. H.A. Ehrlich, Ed., Stockton Press, NY; Yap et al, Nucl. Acids. Res. 19: 4294, 1991).
- a biological sample obtained from a patient may be analyzed for one or more mutations in the IAP or NAIP sequences or p53 sequences using a mismatch detection approach.
- these techniques involve PCR amplification of nucleic acid from the patient sample, followed by identification of the mutation (i.e., mismatch) by either altered hybridization, aberrant electrophoretic gel migration, binding or cleavage mediated by mismatch binding proteins, or direct nucleic acid sequencing.
- Any of these techniques may be used to facilitate mutant IAP or NAIP detection, and each is well known in the art; examples of particular techniques are described, without limitation, in Orita et al, Proc. Natl. Acad. Sci. USA 86: 2766-2770, 1989; Sheffield et al, Proc. Natl. Acad. Sci. USA 86: 232- 236, 1989).
- immunoassays are used to detect or monitor IAP or NAIP protein in a biological sample.
- IAP or NAIP-specific polyclonal or monoclonal antibodies produced as described above may be used in any standard immunoassay format (e.g., ELISA, Western blot, or RJA) to measure IAP or NAIP polypeptide levels from cancerous control cells. These levels would be compared to wild-type IAP or NAIP levels, with a decrease in IAP production relative to a wild-type cell indicating a condition involving increased apoptosis and a decrease relative to a known cancer cell indicating a decreased likelihood of an IAP or NAIP-related cancer.
- Immunohistochemical techniques may also be utilized for IAP or NAIP detection.
- a tissue sample may be obtained from a patient, sectioned, and stained for the presence of IAP or NAIP using an anti-IAP or anti-NAIP antiboies and any standard detection system (e.g., one which includes a secondary antibody conjugated to horseradish peroxidase).
- any standard detection system e.g., one which includes a secondary antibody conjugated to horseradish peroxidase.
- a combined diagnostic method may be employed that begins with an evaluation of IAP or NAIP protein production (for example, by immunological techniques or the protein truncation test (Hogerrorst et al, Nature Genetics 10:208-212, 1995)) and also includes a nucleic acid-based detection technique designed to identify more subtle IAP or NAIP alterations, e.g., mutations. As described above, a number of mismatch detection assays are available to those skilled in the art, and any preferred technique may be used. Mutations in IAP or NAIP may be detected that either result in enhanced IAP or NAIP expression or alterations in IAP or NAIP biological activity. In a variation of this combined diagnostic method, IAP or NAIP biological activity is measured as anti-apoptotic activity using any appropriate apoptosis assay system (for example, those described above).
- Mismatch detection assays also provide an opportunity to diagnose an IAP-mediated or an NAIP-mediated predisposition to diseases caused by insufficient apoptosis.
- a patient heterozygous for an IAP or a NAIP mutation may show no clinical symptoms and yet possess a higher than normal probability of developing one or more types of proliferative diseases.
- a patient may take precautions to minimize their exposure to adverse environmental factors (for example, UV exposure or chemical mutagens) and to carefully monitor their medical condition (for example, through frequent physical examinations).
- This type of IAP or NAIP diagnostic approach may also be used to detect IAP or NAIP mutations in prenatal screens.
- the IAP or NAIP diagnostic assays described above may be carried out using any biological sample (for example, any biopsy sample or bodily fluid or tissue) in which IAP or NAIP is normally expressed. Identification of a mutant IAP or NAIP gene may also be assayed using these sources for test samples. Alternatively, an alteration in IAP or NAIP activity, particularly as part of a diagnosis for predisposition to IAP-associated or NAIP-associated proliferative disease, may be tested using a nucleic acid sample from any cell, for example, by mismatch detection techniques. Preferably, the DNA sample is subjected to PCR amplification prior to analysis. The following examples are meant to illustrate, not limit, the invention.
- a Human Cancer Cell Line Multiple Tissue Northern Blot (Clontech, Palo Alto, CA; #7757-1) was probed. This Northern blot contained approximately 2 ⁇ g of poly A + RNA per lane from eight different human cell lines: (1) promyelocytic leukemia HL-60, (2) HeLa cell S3, (3) chronic myelogenous leukemia K-562, (4) lymphoblastic leukemia MOLT-4, (5) Burkitt's lymphoma Raji, (6) colorectal adenocarcinoma SW480, (7) lung carcinoma A549, and (8) melanoma G361.
- a Human Multiple Tissue Northern Blot (Clontech, Palo Alto, CA; #7759-1) was probed. This Northern blot contained approximately 2 ⁇ g of poly A" RNA from eight different human tissues: (1) spleen, (2) thymus, (3) prostate, (4) testis, (5) ovary, (6) small intestine, (7) colon, and (8) peripheral blood leukocytes.
- the Northern blots were hybridized sequentially with: (1) a 1.6 kb probe to the XIAP coding region, (2) a 375 bp HIAP-2 specific probe corresponding to the 3' untranslated region, (3) a 1.3 kb probe to the coding region of HIAP-1, which cross-reacts with HIAP-2, (4) a 1.0 kb probe derived from the coding region of BCL-2, and (5) a probe to ⁇ -actin, which was provided by the manufacturer. Hybridization was carried out at 50 °C overnight, according to the manufacturer's suggestion. The blot was washed twice with 2X SSC, 0.1% SDS at room temperature for 15 minutes and then with 2X SSC, 0.1% SDS at 50°C.
- Levels are indicated by a (+) and are the approximate increase in RNA levels relative to Northern blots of RNA from non-cancerous control cell lines. A single plus indicates an estimated increase of at least 1-fold
- upregulation ofthe anti-apoptotic IAP genes may be a widespread phenomenon in proliferative diseases, perhaps occurring much more frequently than upregulation of BCL-2. Furthermore, upregulation may be necessary for the establishment or maintenance ofthe transformed state of cancerous cells.
- Thermocycler to carry out 35 cycles of the following program: 94°C for 1 minute, 50°C for 1.5 minutes, and 72°C for 1 minute.
- the PCR reaction product was electrophoresed on an agarose gel and stained with ethidium bromide. Amplified cDNA fragments ofthe appropriate size were clearly visible in all lanes containing Burkitt's lymphoma samples, but absent in the lanes containing the normal placental tissue sample, and absent in lanes containing negative control samples, where template DNA was omitted from the reaction (Fig. 11).
- EXAMPLE 2 IAPs IN BREAST CANCER
- MCF-7 clone 1, wt p53
- MCF-7 clone 2, wt p53
- MCF-7 American Type Culture Collection, wt ⁇ 53
- MCF-7 parental line, California, wt p53
- MCF-7 California, adriamycin resistant variant, mutant p53
- MDA MB 231 (ATCC, mutant p53, codon 280); 7. T47-D (ATCC, mutant p53, codon 194); 8. ZR-75 (ATCC, wt p53).
- GPDH glycerol phosphate dehydrogenase
- Epithelial ovarian cancer is the leading cause of death from gynecologic malignancy. Although clinical and histologic prognostic factors such as tumor grade and surgical stage are well understood, the biologic process that leads to uncontrolled cellular growth is less clear. The control of cell numbers during tissue growth is thought to be the results of a balance of cell proliferation and cell death. An aberration in this natural homeostasis likely contributes to malignant cellular transformation.
- Cisplatin-sensitive (OV2008) and cisplatin-resistant (C13) human ovarian epithelial cells were cultured in a chemically-defined medium at 37 °C for up to 48 hours in the presence or absence of TGF ⁇ (20 ng/ml), taxol (0 - 1.0 ⁇ M) or cisplatin (0 - 30 ⁇ M).
- TGF ⁇ 20 ng/ml
- taxol 0. - 1.0 ⁇ M
- cisplatin 0. - 30 ⁇ M
- DNA ladders For quantitation of DNA ladders, cellular DNA was extracted using the Qiagen Blood kit (Qiagen Inc., Chatsworth, CA). DNA was quantified by ethidium bromide fluorescence. DNA (0.5 ⁇ g) was then end labelled by incubating (20 min., room temp.) with Klenow enzyme (2 U in 10 mM Tris plus 5 mM MgCl 2 ) and 0.1 ⁇ Ci [ ⁇ 32 P]dCTP. Unincorporated nucleotides were removed with the Qiagen nucleotide removal kit and samples were resolved by Tris-acetate-EDTA agarose (1.8%) gel electrophoresis.
- the gel was then dried (2 hours, no heat) and exposed to a Bio-Rad phosphoimager screen to densitometrically quantify low molecular weight DNA ( ⁇ 15 kilo base-pairs), and subsequently to X-ray film at -80°C.
- the in situ cell death detection kit Boehringer-Mannheim, Indianapolis, IN was used, according to manufacturer's instructions. Slides prepared for histology were treated (20 min. at 37°C) with terminal transferase in the presence of FITC-conjugated dUTP.
- Protein extracts were prepared from human surface epithelial cancer cells sonicated (8 sec/cycle, 3 cycles) on ice in sucrose buffer (0.25 M sucrose, 0.025 M NaCl, 1 mM EGTA and 15 mM Tris-HCl pH 6.8, supplemented with 1 mM PMSF, 2 ⁇ g/ml of leupeptin and 5 ⁇ g/ml of aprotinin.
- sucrose buffer 0.25 M sucrose, 0.025 M NaCl, 1 mM EGTA and 15 mM Tris-HCl pH 6.8, supplemented with 1 mM PMSF, 2 ⁇ g/ml of leupeptin and 5 ⁇ g/ml of aprotinin.
- the sonicates were centrifuged at 13,000xg for 10 min., the supematants were collected and stored at -20 °C until electrophoretic analyses were performed. Protein concentration was determined by Bio-Rad Protein Assay.
- Proteins (10-30 ⁇ g) were resolved by one-dimensional SDS-PAGE, and electrophoretically transferred to nitrocellulose membrane. Membranes were blocked with 5% non-fat milk, and subsequently incubated with rabbit polyclonal antibody for IAP [anti-human HIAP-2 ⁇ E (960529; 1:1000 dilution), anti-human NAIP E 1.0 (951015; 1:1000 dilution) or anti-human XIAP (1:1000 dilution)] diluted in TBST (10 mM Tris-buffered saline, 0.1% Tween-20, pH7.5) containing 5% milk. An ECL kit was used to visualize immunopositive protein (Amersham Intl., Arlington Heights, IL).
- RNA from ovarian surface epithelial cancer cells by using RNeasy Kit (Qiagen).
- the RNA samples (10-15 ⁇ g) were quantified spectrophotometrically and size- fractioned by electrophoresis on formaldehyde-agarose gels (1.1%) containing 1 ⁇ g/ml ethidium bromide to confirm even loading of RNA samples and adequate separation of 28S and 18S ribosomal bands.
- the RNAs bands were blotted onto a nylon membrane and cross- linked by UV light.
- Membranes were prehybridized in 50% formamide, saline sodium citrate (SSC; 750 mM NaCl, 75 mM sodium citrate), IX Denhardt's solution, 1% SDS, 4 mM EDTA and 100 ⁇ g/ml sheared salmon sperm DNA for 4 hours at 42°C. Hybridization was performed overnight at 42 °C with 20 million cpm of 32 P-labelled IAP cDNA probes (rat NAIP, rat XIAP or human HIAP-2) added to the prehybridization buffer.
- SSC saline sodium citrate
- IX Denhardt's solution 1% SDS
- 4 mM EDTA 100 ⁇ g/ml sheared salmon sperm DNA
- the membranes were then washed twice with SSC (300 mM NaCl, 30 mM sodium citrate) in 0.1% SDS for 20 min at room temperature and twice with SSC (30 mM NaCl, 3 mM sodium citrate) in 0.1% SDS for 20 min at 55°C and exposed to X-ray film at -80°C for visualization. Densitometric analysis of various IAPs and 28S rRNA band was performed with the Image Analysis Systems from Bio-Rad Laboratories. Data were normalized by the respective 28S and expressed as a percentage ofthe control (defined as 100%).
- Cisplatin induced a concentration-dependent increase in the incidence of apoptosis in cisplatin-sensitive (OV2008) but to a lesser extent in -resistant (C13) human ovarian epithelial cells in vitro (Fig. 20).
- Taxol also induced apoptosis in OV2008 cells, but to a lesser extent in the C13 cells (Fig. 21).
- XIAP and HIAP-2 protein contents were markedly higher in cisplatin-sensitive than -resistant cells.
- Taxol (0.04-1.0 ⁇ M) decreased XIAP and HIAP-2 protein levels in a concentration-dependent manner, the response being more pronounced in sensitive than resistant cells (Fig. 22).
- a lower molecular weight (approx. 45 kDa) immunoreactive fragment of HIAP-2 was also evident in both the sensitive and resistant cells. The content of this fragment was increased in the C13 cells but decreased in OV2008 cells by Taxol (Fig. 22).
- Taxol (0.2 ⁇ M) marked suppressed HIAP-2 mRNA abundance in cisplatin- sensitive cells (approx. 80%), it was ineffective in the resistant cells (Fig. 23).
- TGF ⁇ (20ng/ml) induced apoptosis in OV2008 but not in Cl 3. Although its influence on XIAP protein content in cisplatin-resistant cells was only marginal, it markedly suppressed the protein level of this IAP in the cisplatin-sensitive cells (Fig. 24A, 24B). TGF ⁇ (20 ng/ml) also decreased HIAP-2 mRNA in OV2008 but not C13 cells (Fig. 23).
- Induction of apoptosis in human ovarian epithelial cancer cell by Taxol was accompanied by suppressed IAP gene expression.
- Eventual loss of sensitivity of the cells to the chemotherapeutic agent may be associated with the decreased ability of the cell to express IAP genes.
- the decreased HIAP-2 protein content in the face of an absence of noticeable change in HIAP-2 mRNA abundance
- Taxol was accompanied an increase in the intensity of a 45 kDa immunoreactive HIAP-2 protein band.
- EXAMPLE 4 Accumulation of a 26 kDa Cleavage Protein in Astrocytoma Cells
- a total protein extract was prepared from Jurkat and astrocytoma cells by sonicating them (X3 for 15 seconds at 4°C) in 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM PMSF, 1 ⁇ g/ml aprotinin, and 5 mM benzamidine. Following sonication, the samples were centrifuged (14,000 RPM in a micro centrifuge) for five minutes. 20 ⁇ g of protein was loaded per well on a 10% SDS-polyacrylamide gel, electrophoresed, and electroblotted by standard methods to PVDF membranes.
- a 26 kDa XIAP -reactive band was also observed under the following experimental conditions.
- Jurkat cells a transformed human T cell line
- an anti-Fas antibody (1 ⁇ g/ml).
- Identical cultures of Jurkat cells were exposed either to: (1) anti-Fas antibody and cycloheximide (20 ⁇ g/ml), (2) tumor necrosis factor alpha (TNF- ⁇ , at 1,000 U/ml), or (3) TNF- ⁇ and cycloheximide (20 ⁇ g/ml). All cells were harvested 6 hours after treatment began.
- anti-Fas antibody was added to an extract after the cells were harvested.
- the cells were harvested in SDS sample buffer, electrophoresed on a 12.5% SDS polyacrylamide gel, and electroblotted onto PVDF membranes using standard methods.
- the membranes were immunostained with a rabbit polyclonal anti-XIAP antibody at 1 :1000 for 1 hour at room temperature. Following four 15 minute washes, a goat anti-rabbit antibody conjugated to horse-radish peroxidase was applied at room temperature for 1 hour. Unbound secondary antibody was washed away, and chemiluminescent detection of XIAP protein was performed.
- the Western blot revealed the presence of the full-length, 55 kDa XIAP protein, both in untreated and treated cells. In addition, a novel, approximately 26 kDa XIAP-reactive band was also observed in apoptotic cell extracts, but not in the control, untreated cell extracts (Fig. 13).
- Cleavage of XIAP occurs in a variety of cell types, including other cancer cell lines such as HeLa.
- the expression ofthe 26 kDa XIAP cleavage product was demonstrated in HeLa cells as follows. HeLa cells were treated with either: (1) cyclohexamide (20 ⁇ g/ml), (2) anti-Fas antibody (1 ⁇ g/ml), (3) anti-Fas antibody (1 ⁇ g/ml) and cyclohexamide (20 ⁇ g/ml), (4) TNF ⁇ (1,000 U/ml), or (5) TNF ⁇ (1,000 U/ml) and cyclohexamide (20 ⁇ g/ml). All cells were harvested 18 hours after treatment began. As above, anti-Fas antibody was added to an extract after the cells were harvested. HeLa cells were harvested, and the
- Jurkat cells were induced to undergo apoptosis by exposure to anti-Fas antibody (1 ⁇ g/ml) and were then harvested either immediately, 3 hours, or 7 hours later.
- Total protein extracts were prepared, as described above, from cells harvested at each time point.
- apoptotic Jurkat cells were washed with isotonic Tris buffered saline (pH 7.0) and lysed by freezing and thawing five times in cell extraction buffer (50 mM PIPES, 50 mM KC1, 5 mM EGTA, 2 mM MgCl 2 , 1 mM DTT, and 20 ⁇ M cytochalasin B). Nuclei were pelleted by centrifugation and resuspended in isotonic Tris (pH 7.0) and frozen at -80 °C.
- the cytoplasmic fraction ofthe extract was processed further by centrifugation at 60,000 RPM in a TA 100.3 rotor for 30 minutes. Supematants were removed and frozen at -80°C. Samples of both nuclear and cytoplasmic fractions were loaded on a 12.5% SDS-polyacrylamide gel, and electroblotted onto PVDF membranes. Western blot analysis was then performed using either an anti-CPP32 antibody (Transduction Laboratories Lexington, KY; Fig. 16A) or the rabbit anti-XIAP antibody described above (Fig. 16B).
- the anti-CPP32 antibody which recognizes the CPP32 protease (also known as YAMA or Apopain) partitioned almost exclusively in the cytoplasmic fraction.
- the 55 kDa XIAP protein localized exclusively in the cytoplasm of apoptotic cells, in agreement with the studies presented above, where XIAP protein in normal, healthy COS cells was seen to localize, by immunofluoresence microscopy, to the cytoplasm.
- the 26 kDa cleavage product localized exclusively to the nuclear fraction of apoptotic Jurkat cells.
- XIAP protein was labeled with 35 S using the plasmid pcDNA3-6myc-XIAP, T7 RNA polymerase, and a coupled transcription/translation kit (Promega, Madison, WI) according to the manufacturer's instructions. Radioactively labeled XIAP protein was separated from unincorporated methionine by column chromatography using Sephadex G-50TM. In addition, extracts of apoptotic Jurkat cells were prepared following treatment with anti-Fas antibody (1 ⁇ g/ml) for three hours.
- the cells were lysed in Triton X-100 buffer (1% Triton X-100, 25 mM Tris HCl) on ice for two hours and then microcentrifuged for 5 minutes. The soluble extract was retained (and was labeled TX100). Cells were lysed in cell extraction buffer with freeze/thawing. The soluble cytoplasmic fraction was set aside (and labeled CEB). Nuclear pellets from the preparation of the CEB cytoplasmic fraction were solubilized with Triton X-100 buffer, microcentrifuged, and the soluble fractions, which contains primarily nuclear DNA, was retained (and labeled CEB-TX100).
- Triton X-100 buffer 1% Triton X-100, 25 mM Tris HCl
- Soluble cell extract was prepared by lysing cells with NP-40 buffer, followed by microcentrifugation for 5 minutes (and was labeled NP-40). In vitro cleavage was performed by incubating 16 ⁇ l of each extract (CEB, TX-100, CEB- TX100, and NP-40) with 4 ⁇ l of in vitro translated XIAP protein at 37°C for 7 hours. Negative controls, containing only TX100 buffer or CEB buffer were also included. The proteins were separated on a 10% SDS-polyacrylamide gel, which was dried and exposed to X-ray film ovemight.
- EXAMPLE 5 CHARACTERIZATION OF TAP ACTIVITY AND INTRACELLULAR LOCALIZATION STUDIES
- IAPs to modulate apoptosis
- Mammalian expression constructs carrying IAP cDNAs which are either full-length truncated, or antisense constmcts can be introduced into cell lines such as CHO, NIH 3T3, HL60, Rat-1, or Jurkat cells.
- SF21 insect cells may be used, in which case the IAP gene is preferentially expressed using an insect heat shock promoter.
- apoptosis can be induced by standard methods, which include semm withdrawal, or application of staurosporine, menadione (which induces apoptosis via free radial formation), or anti-Fas antibodies.
- cells are cultured under the same conditions as those induced to undergo apoptosis, but either not transfected, or transfected with a vector that lacks an IAP insert.
- the ability of each IAP related constmct to inhibit or enhance apoptosis upon expression can be quantified by calculating the survival index of the cells, i.e., the ratio of surviving transfected cells to surviving control cells.
- Figs. 10A to 10D Specific examples of the results obtained by performing various apoptosis suppression assays are shown in Figs. 10A to 10D.
- CHO cell survival following transfection with one of six constmcts and subsequent semm withdrawal is shown in Fig. 10A.
- the cells were transfected using LipofectaceTM with 2 ⁇ g of one ofthe following recombinant plasmids: pCDNA36myc-xiap (XIAP), pCDNA3-6myc-hiap-l (HIAP-1), pCDNA3-6myc-hiap-2 (HIAP-2), pCDNA3-bcl-2 (BCL-2), pCDNA3-HA-smn (SMN), and pCDNA3-6myc (6-myc).
- Oligonucleotide primers were synthesized to allow PCR amplification and cloning ofthe XIAP, HIAP-1, and HIAP-2 ORFs in pCDNA3
- Fig. 10B The survival of CHO cells following transfection (with each one ofthe six constmcts described above) and exposure to menadione is shown in Fig. 10B.
- the cells were plated in 24-well dishes, allowed to grow ovemight, and then exposed to 20 ⁇ M menadione for 1.5 hours (Sigma Chemical Co., St. Louis, MO). Triplicate samples were harvested at the time of exposure to menadione and 24 hours afterward, and survival was assessed by trypan blue exclusion.
- Rat-1 cells were transfected and then selected in medium containing 800 ⁇ g/ml G418 for two weeks. The cell line was assessed for resistance to staurosporine-induced apoptosis (1 ⁇ M) for 5 hours. Viable cells were counted 24 hours after exposure to staurosporine by trypan blue exclusion. The percentage of viable cells shown represents the average of two experiments, +/- average deviation.
- the Rat-1 cell line was also used to test the resistance of these cells to menadione
- FIG. 10D following transfection with each ofthe six constmcts described above.
- the cells were exposed to 10 ⁇ M menadione for 1.5 hours, and the NUMBER of viable cells was counted 18 hours later.
- EXAMPLE 7 COMPARISON OF CELL SURVIVAL FOLLOWING TRANSFECTION WITH FULL-LENGTH VS. PARTIAL IAP CONSTRUCTS
- expression vectors were constmcted that contained either: (1) full-length IAP cDNA (as described above), (2) a portion of an IAP gene that encodes the BIR domains, but not the RZF, or (3) a portion of an IAP gene that encodes the RZF, but not the BIR domains.
- Human and murine XIAP cDNAs were tested by transient or stable expression in HeLa, Jurkat, and CHO cell lines. Following transfection, apoptosis was induced by semm withdrawal, application of menadione, or application of an anti-Fas antibody. Cell death was then assessed, as described above, by trypan blue exclusion. As a control for transfection efficiency, the cells were co-transfected with a ⁇ -gal expression constmct. Typically, approximately 20% ofthe cells were successfully transfected.
- constmcts containing full-length human or mouse xiap cDNAs conferred modest but definite protection against cell death.
- the survival of CHO cells transfected with constmcts encoding only the BIR domains was markedly enhanced 72 hours after semm deprivation.
- a large percentage of cells expressing the BIR domains were still viable after 96 hours, at which time no viable cells remained in the control, i.e. non- transfected, cell cultures, and less than 5% of the cells transfected with the vector only, i.e., lacking a cDNA insert, remained viable. Deletion of any of the BIR domains results in the complete loss of apoptotic suppression, which is reflected by a decrease in the percentage of surviving CHO cells to control levels within 72 hours of semm withdrawal.
- Stable pools of transfected CHO cells which were maintained for several months under G418 selection, were induced to undergo apoptosis by exposure to 10 ⁇ M menadione for 2 hours.
- CHO cells tested were those that were stably transfected with: (1) full-length mu ⁇ ne XIAP cDNA (MIAP), (2) full-length XIAP cDNA (XIAP), (3) full-length BCL-2 cDNA (BCL-2), (4) cDNA encoding the three BIR domains (but not the RZF) of murine XIAP (BIR), and (5) cDNA encoding the RZF (but not BIR domains) of M-XIAP (RZF).
- MIAP full-length mu ⁇ ne XIAP cDNA
- XIAP full-length XIAP cDNA
- BCL-2 full-length BCL-2 cDNA
- RZF cDNA encoding the three BIR domains (but not the RZF
- the percentage of viable CHO cells that expressed the BIR domain cDNA constmct was higher than the percentage of viable cells that expressed either full-length murine XIAP or BCL-2.
- EXAMPLE 8 ANALYSIS OF THE SUBCELLULAR LOCATION OF EXPRESSED RZF AND BIR DOMAINS
- the assays of cell death described above indicate that the RZF acts as a negative regulator of the anti-apoptotic function of IAPs.
- One way in which the RZF, and possibly other IAP domains, may exert their regulatory influence is by altering the expression of genes, whose products function in the apoptotic pathway.
- COS cells were transiently transfected with the following four constmcts, and the expressed polypeptide was localized by immunofluorescent microscopy: (1) pcDNA3-6myc-XIAP, which encodes all 497 amino acids of SEQ ID NO: 4, (2) pcDNA3-6myc-m-XIAP, which encodes all 496 amino acids of mouse XIAP (SEQ ID NO: 10), (3) pcDNA3-6myc-mxiap-BIR, which encodes amino acids 1 to 341 of m-XIAP, and (4) pcDNA3-6myc-mxiap-RZF, which encodes amino acids 342- 496 of murine XIAP.
- pcDNA3-6myc-XIAP which encodes all 497 amino acids of SEQ ID NO: 4
- pcDNA3-6myc-m-XIAP which encodes all 496 amino acids of mouse XIAP (SEQ ID NO: 10)
- pcDNA3-6myc-mxiap-BIR
- the cells were grown on multi-well tissue culture slides for 12 hours, and then fixed and permeabilized with methanol.
- the constmcts used (here and in the cell death assays) were tagged with a human Myc epitope tag at the N-terminus. Therefore, a monoclonal anti-Myc antibody and a secondary goat anti-mouse antibody, which was conjugated to FITC, could be used to localize the expressed products in transiently transfected COS cells.
- Full-length XIAP and MIAP were located in the cytoplasm, with accentuated expression in the peri-nuclear zone. The same pattem of localization was observed when the cells expressed a constmct encoding the RZF domain (but not the BIR domains). However, cells expressing the BIR domains (without the RZF) exhibited, primarily, nuclear staining.
- the protein expressed by the BIR domain constmct appeared to be in various stages of transfer to the nucleus.
- the panel may consist of approximately four types of recombinant vims
- A) Sense orientation vimses for each of the IAP or NAIP open reading frames XIAP, HIAP- 1 , HIAP-2, and NAIP These vimses are designed to massively overexpress the recombinant protein in infected cells
- C) Sub-domain expression vimses These constmcts express only a partial IAP protein in infected cells Our results indicate that deletion of the zinc fmger of XIAP renders the protein more potent in protecting cell against apoptotic triggers This data also indicates that expression of the zinc finger alone will indicate
- Verification of the sense adenovims function involves infection of tissue culture cells and determination of protein expression levels
- the remaining vimses may be ready readily assessed for protein expression using the polyclonal IAP antibodies
- Functional analysis of the antisense vimses may be done at the RNA level using either northern blots of total RNA harvested from infected tissue culture cells or ⁇ bonuclease protection assays Western blot analysis of infected cells will be used to determine whether the expressed antisense RNA interferes with IAP expression m the host cell
- IAP overexpression results in increased drug resistance We have optimized cell death assays to allow high through-put of samples with minimal sample variation. Testing ofthe sense IAP adenovimses for their ability to alter dmg sensitivity of breast and pancreatic adenocarcinoma cell lines may be accomplished as follows. Cancer cell lines are infected with the recombinant vimses, cultured for 5 days, then subdivided into 24 well plates. Triplicate cell receive increasing concentrations of the anti-cancer dmg under investigation. Samples are harvested at 24, 48, and 72 hours post exposure, and assayed for the number of viable cells in the well. The dose response curve is then compared to uninfected and control vims (both positive and negative) infected cells.
- oligonucleotide determines whether a particular oligonucleotide will be effective, necessitating several oligonucleotides for each IAP.
- Five oligonucleotides have been made for each IAP mRNA based on the available computer algorhythms for predicting binding affinities and mRNA secondary stmctures. These and other oligonucleotides may be tested for their ability to target their respective mRNAs for degradation using northern blot analysis. 6. Optimization of oligonucleotides .
- a secondary round of oligonucleotides may be made when effective target regions have been identified. These oligonucleotides target sequences in the immediate vicinity ofthe most active antisense oligonucleotides identified using methods such as those provided above. A second round of testing by northern blot analysis may be required.
- Preliminary assessment of an antisense IAP therapeutic involves injection of cancer cells infected with the recombinant adenovimses (sense, antisense, and control vimses) under the skin, and the tumorigenic index compared to that of untreated cells.
- adenovimses sense, antisense, and control vimses
- This type of antisense oligonucleotide has demonstrated enhanced cell permeability and slower clearance rates from the body in experimental animal models.
- apoptosis assays are also provided in the following references. 5 Assays for apoptosis in lymphocytes are disclosed by: Li et al, Science 268: 429-431, 1995; Gibellini et al, Br. J. Haematol. 89: 24-33, 1995; Martin et al, J. Immunol. 152: 330-342, 1994; Terai et al, J. Clin Invest. 87: 1710-1715, 1991; Dhein et al, Nature 373: 438-441, 1995; Katsikis et al, J. Exp. Med.
- IAP and NAIP genes provided information that necessary for 25 generation IAP and NAIP transgenic animal models to be developed by homologous recombination (for knockouts) or transfection (for expression of IAP or NAIP fragments, antisense nucleic acids, or increased expression of wild-type or mutant IAPs or NAIP).
- Such a model may be a mammalian animal, e.g., a mouse, and is useful for the identification of cancer therapeutics alone or in combination with cancer inducing cells or agents, or when such mice are crossed with mice genetically predisposed to cancers.
- the preferred transgenic animal overexpression in IAP or NAIP and has a predisposition to cancer has a predisposition to cancer. This mouse is particularly useful for the screening of potential cancer therapeutics.
- IAP and NAIP genes and fragments thereof may be expressed in both prokaryotic and eukaryotic cell types. If an IAP or NAIP fragment enhances apoptosis, it may be desirable to express that protein under control of an inducible promoter.
- IAPs and NAIP, and fragments thereof may be produced by transforming a suitable host cell with all or part of the IAP-encoding or NAIP-encoding cDNA fragment that has been placed into a suitable expression vector.
- the IAP protein may be produced in a prokaryotic host (e.g., E. coli) or in a eukaryotic host (e.g., S. cerevisiae, insect cells such as Sf21 cells, or mammalian cells such as COS-1, NIH 3T3, or HeLa cells, or other highly proliferative cell types). These cells are publically available, for example, from the American Type Culture Collection, Rockville, MD; see also Ausubel et al, supra).
- a prokaryotic host e.g., E. coli
- a eukaryotic host e.g., S. cerevisiae, insect cells such as Sf21 cells, or mammalian cells such as COS-1, NIH 3T3, or HeLa cells, or other highly proliferative cell types.
- transduction and the choice of expression vehicle will depend on the host system selected. Transformation and transfection methods are described, e.g., in Ausubel et al. (supra), and expression vehicles may be chosen from those provided, e.g., in Cloning Vectors: A Laboratory Manual (P.H. Pouwels et al, 1985, Supp. 1987).
- Polypeptides of the invention can also be produced by chemical synthesis (e.g., by the methods described in Solid Phase Peptide Svnthesis. 2nd ed., 1984 The Pierce Chemical Co., Rockford, IL). These general techniques of polypeptide expression and purification can also be used to produce and isolate useful IAP fragments or analogs, as described herein.
- an IAP or NAIP coding sequence (e.g., amino acids 180-276) can be expressed as a C-terminal fusion with glutathione S-transferase (GST; Smith et al. Gene 67: 31-40, 1988).
- the fusion protein can be purified on glutathione-Sepharose beads, eluted with glutathione, and cleaved with thrombin (at the engineered cleavage site), and purified to the degree required to successfully immunize rabbits.
- Antibody titres are monitored by Western blot and immunoprecipitation analyses using the thrombin-cleaved IAP fragment ofthe GST-IAP and GST-NAIP fusion proteins. Immune sera are affinity purified using CNBr-Sepharose-coupled IAP protein. Antisemm specificity is determined using a panel of unrelated GST proteins (including GSTp53, Rb, HPV-16 E6, and E6-AP) and GST-trypsin (which was generated by PCR using known sequences).
- peptides corresponding to relatively unique hydrophilic regions of IAP or NAIP may be generated and coupled to keyhole limpet hemocyanin (KLH) through an introduced C-terminal lysine.
- KLH keyhole limpet hemocyanin
- Antisemm to each of these peptides is similarly affinity purified on peptides conjugated to BSA, and specificity is tested by ELISA and Western blotting using peptide conjugates, and by Western blotting and immunoprecipitation using IAP or NAIP expressed as a GST fusion protein.
- monoclonal antibodies may be prepared using the IAP or NAIP proteins described above and standard hybridoma technology (see, e.g., Kohler et al, Nature 256: 495, 1975; Kohler et al, Eur. J. Immunol. 6: 511, 1976; Kohler et al, Eur. J. Immunol. 6:292, 1976; Hammerling et al, In Monoclonal Antibodies and T Cell Hybridomas. Elsevier, New York, NY, 1981 ; Ausubel et al, supra). Once produced, monoclonal antibodies are also tested for specific IAP or NAIP recognition by Western blot or immunoprecipitation analysis (by the methods described in Ausubel et al, supra).
- Antibodies that specifically recognize IAPs or NAIP or fragments thereof, such as those described herein containing one or more BIR domains (but not a ring zinc fmger domain), or that contain a ring zinc finger domain (but not a BIR domain) are considered useful in the invention. They may, for example, be used in an immunoassay to monitor IAP or NAIP expression levels or to determine the subcellular location of an IAP or NAIP (or fragment thereof) produced by a mammal. Antibodies that inhibit the 26 kDa IAP cleavage product described herein (which contains at least one BIR domain) may be especially useful in inducing apoptosis in cells undergoing undesirable proliferation.
- antibodies of he invention are produced using IAP or NAIP sequence that does not reside within highly conserved regions, and that appears likely to be antigenic, as analyzed by criteria such as those provided by the Peptide structure program (Genetics Computer Group Sequence Analysis Package, Program Manual for the GCG Package, Version 7, 1991) using the algorithm of Jameson and Wolf (CABIOS 4: 181, 1988).
- these regions which are found between BIR1 and BIR2 of all IAPs, are: from amino acid 99 to amino acid 170 of HIAP- 1, from amino acid 123 to amino acid 184 of HIAP-2, and from amino acid 1 16 to amino acid 133 of either XIAP or m-XIAP.
- fragments can be generated by standard techniques, e.g., by the PCR, and cloned into the pGEX expression vector (Ausubel et al, supra). Fusion proteins are expressed in E. coli and purified using a glutathione agarose affinity matrix as described in Ausubel et al. (supra). In order to minimize the potential for obtaining antisera that is non-specific, or exhibits low- affinity binding to IAP, two or three fusions are generated for each protein, and each fusion is injected into at least two rabbits. Antisera are raised by injections in series, preferably including at least three booster injections.
- EXAMPLE 14 IDENTIFICATION OF MOLECULES THAT MODULATE THE EXPRESSION OR BIOLOGICAL ACTIVITY OF AN IAP OR NAIP GENE
- IAP and NAIP cDNAs facilitate the identification of molecules that decrease IAP or NAIP expression or otherwise enhance apoptosis normally blocked by these polypeptides.
- Such compounds are highly useful as, for example, chemotherapeutic agents to destroy a cancer cell, or to reduce the growth of a cancer cell, where the cancer cell is one, as is described herein, with an elevated level of an IAP or NAIP polypeptide.
- candidate molecules are added, in varying concentration, to the culture medium of cells expressing IAP or NAIP mRNA.
- IAP or NAIP expression is then measured, for example, by Northern blot analysis (Ausubel et al, supra) using an IAP or NAIP cDNA, or cDNA fragment, as a hybridization probe.
- the level of IAP or NAIP expression in the presence ofthe candidate molecule is compared to the level of IAP or NAIP expression in the absence ofthe candidate molecule, all other factors (e.g., cell type and culture conditions) being equal.
- the effect of candidate molecules on IAP- or NAIP-mediated apoptosis may, instead, be measured at the level of protein or the level of polypeptide fragments of IAP or NAIP polypeptides using the general approach described above with standard polypeptide detection techniques, such as Western blotting or immunoprecipitation with an IAP or NAIP-specific antibodies (for example, the antibodies described herein).
- Compounds that modulate the level of a IAP or NAIP polypeptide may be purified, or substantially purified, or may be one component of a mixture of compounds such as an extract or supematant obtained from cells (Ausubel et al. supra). In an assay of a mixture of compounds, IAP or NAIP polypeptide expression is tested against progressively smaller subsets ofthe compound pool (e.g., produced by standard purification techniques such as HPLC or FPLC) until a single compound or minimal number of effective compounds is demonstrated to modulate IAP or NAIP expression.
- Compounds may also be screened for their ability to modulate the biological activity of an IAP or NAIP polypeptide by, for example, an ability to enhance IAP- or NAIP- mediated apoptosis.
- the degree of apoptosis in the presence of a candidate compound is compared to the degree of apoptosis in its absence, under equivalent conditions.
- the screen may begin with a pool of candidate compounds, from which one or more useful modulator compounds are isolated in a step-wise fashion.
- Apoptosis activity may be measured by any standard assay, for example, those described herein.
- Another method for detecting compounds that modulate the expression or biological activity of an IAP or a NAIP polypeptide is to screen for compounds that interact physically with a given IAP polypeptide.
- These compounds may be detected by adapting two hybrid systems known in the art. These systems detect protein interactions using a transcriptional activation assay and are generally described by Gyuris et al. (Cell 75: 791-803, 1993) and Field et al. (Nature 340: 245-246, 1989), and are commercially available from Clontech (Palo Alto, CA).
- PCT Publication WO 95/28497 describes a two hybrid system in which proteins involved in apoptosis, by virtue of their interaction with BCL-2, are detected.
- a similar method may be used to identify proteins and other compounds that interact with IAP or NAIP polypeptides.
- Compounds or molecules that function as modulators of IAP-mediated cell death may include peptide and non-peptide molecules such as those present in cell extracts, mammalian semm, or growth medium in which mammalian cells have been cultured.
- compounds previously known for their abilities to modulate apoptosis in cancer cells may be tested for an ability to modulate expression of an IAP molecule.
- EXAMPLE 15 ROLE OF IAPs IN HUMAN OVARIAN CANCER RESISTANCE TO CISPLATIN
- Ovarian epithelial cancer cell apoptosis has been demonstrated to be involved in cisplatin-induced cell death (Hovicesky et al, Obstet. Gynecol. 85: 1007-1010, 1995; Anthoney et al, Cancer Res. 56: 1374-1381, 1996).
- the action of cisplatin is thought to involve the formation of inter and intra-strand DNA crosslinks (Sherman et al, Science 230: 412-417, 1985) although the events leading to cell death after cisplatin treatment is unclear. If IAPs are indeed key elements in the regulation of apoptosis in ovarian cancer cells, one would expect that down-regulation of this anti-apoptotic protein would result in cell death.
- cisplatin-sensitive human ovarian surface epithelial cells (OV2008) were infected with either adenoviral XIAP antisense, adenoviral HIAP-2 antisense, or the empty vector with LacZ (as control) for up to 60 hours, at which time changes in cell morphology, apoptotic cell number, cell viability, and total cell number were determined.
- the full length sense and antisense constmcts of XIAP and HIAP-2 were prepared as briefly described hereafter. To constmct the adenovimses, the open reading frame for XIAP and HIAP-2 were PCR amplified with primers corresponding to the amino and carboxy terminus.
- PCR products were cloned in the pCR2.1 vector (InvitroGen, Carlsbad, CA), and sequenced.
- the ORFs were then excised with EcoRI digestion, blunt ended with Klenow fragment, and ligated into Swal digested pAdexlCAwt cosmid DNA.
- Packaging was performed with Promega (Madison, WI) cosmid packaging extracts and used to infect E. coli. Colonies were picked and screened for the presence ofthe insert in both the sense and antisense orientation relative to the chicken B-actin (CA) promoter.
- CsCl purified cosmid DNA was co- transfected with wild-type adenovims DNA, which contains the terminal protein complexed to the ends ofthe DNA.
- Wild type adenovims DNA was cut with Nsil such that only homologous recombinant with the cosmid DNA generated infectious adenovims DNA.
- the final recombinant adenovims contains a linear, double stranded genome of 44,820 bp plus the insert size (approximately 1,500 for XIAP, approximately 1,800 for HIAP-2).
- Fig. 26A black arrows in left “b” photograph.
- Nuclear fragmentation Fig. 26B, white arrows in photographs “b” and “d”
- Fig 26B photographs “b” and “d” compared to "a” and "c” is also induced in OV2008 cells following 60 hours of infection with adenovims XIAP antisense.
- apoptotic cell number in response to cisplatin was also concentration-dependent and was significant (50% vs. 2%; p ⁇ 0.05) even at a concentration of 10 ⁇ M cisplatin (Fig. 27C). As shown in Figs.
- XIAP and HIAP-2 are present in the cisplatin-sensitive human ovarian surface epithelial cancer cell line OV2008 (protein sizes 55kDa and 68 kDa, respectively), their expression were down-regulated by cisplatin in a concentration-dependent manner.
- XIAP appearing more responsive to the anti-cancer agent. While XIAP protein content was decreased by almost 80% (p ⁇ 0.01) in the presence 20 ⁇ M cisplatin. the decrease of HIAP-2 protein content was not suppressed by cisplatin (Figs. 28A and 28B).
- XIAP protein content was decreased in A2780s (as in OV2008 cells) and not significantly altered in A2780cp (as in C13 cells) in the presence ofthe chemotherapeutic agent.
- XIAP expression is indeed the an important determinant in chemo- resistance in human ovarian surface epithelial cancer
- the influence of cisplatin on XIAP protein content and apoptosis in OV2008 cells following adenoviral XIAP sense infection was investigated. While cisplatin reduced XIAP protein content in OV2008 cells infected with the empty vector (Figs. 31C and 31D, vector plus cisplatin), overexpression ofthe protein with adenoviral sense XIAP cDNA 48 hrs prior to treatment with the chemotherapeutic agent in vitro attenuated the cisplatin effects not only on XIAP protein expression (Figs.
- XIAP may be an important element in human ovarian epithelial cancer chemoresistance.
- XIAP and HIAP-2 were immunlocalized in human ovarian surface epithelial tumors obtained as pathological samples from patients during surgical debulking, using polyclonal antibodies (rabbit polyclonal anti-XIAP and HIAP-2 antibodies were prepared by immunization with human XIAP and HIAP-2 GST fusion protein) against human XIAP and HIAP-2, respectively (Figs. 32C and 32D, respectively).
- polyclonal antibodies rabbit polyclonal anti-XIAP and HIAP-2 antibodies were prepared by immunization with human XIAP and HIAP-2 GST fusion protein
- human XIAP and HIAP-2 were prepared by immunization with human XIAP and HIAP-2 GST fusion protein
- PCNA proliferating cell nuclear antigen: an auxiliary protein of DNA polymerase ⁇ highly expressed as the Gl/S interphase
- XIAP and HIAP-2 immunoreactivity specifically localized in the cytoplasm or the perinuclear region was highest in proliferatively active cells (PCNA positive) and was low or absent in apoptotic cells (TUNEL positive) occasionally found in the tumor specimens.
- an anti-cancer agent that will successfully inhibit the growth ofthe particular cancer of interest.
- One method to detect such an agent is to excise proliferative cells from the cancer of interest, and determine the level of expression and/or level of biological activity of each individual IAP or NAIP polypeptide, and compare these levels to the levels of these polypeptide in a similar cell type from an unaffected individual. For example, if an human female individual has breast cancer (or a neoplasm suspected of being cancerous), cells from the cancer collected, for example, during a biopsy ofthe cancer, can be isolated and, if necessary, propagated in culture.
- the cells can then be analyzed for level of expression and/or level of biological activity of all ofthe IAP and NAIP polypeptides in the cell.
- the expression levels and/or biological activity levels of these polypeptides from the proliferating cells can be compared to the levels of expression and/or biological activity of these polypeptides from normal, healthy cells from a human female individual.
- the comparison is made between on affected (i.e.. abnormally proliferating) and healthy cells ofthe same individual (e.g., cells taken from healthy breast tissue from the individual being tested.
- the level of expression and/or biological activity of each polypeptide in the affected cells is compared to its counterpart in the healthy cells. Any increase in any (or all) ofthe IAP or NAIP polypeptides is detected.
- the cancer is then treated with a compound that decreases expression level or biological activity level of each particular elevated IAP or NAIP polypeptide. Methods for identifying such compounds are described above (see, e.g., Example 14).
- the individual undergoing such analysis and treatment may have already received treatment with an anti-cancer therapeutic agent. It will also be understood that, in addition to targeting the levels of expression and/or biological activities of IAP and NAIP polypeptides, the anti-cancer compounds may also target these levels for other apoptosis-inhibiting polypeptides, such as BCL-2.
- an individual with breast cancer whose proliferating cells have an increased level of XIAP compared to the level of XIAP in healthy breast cells may be treated with a compound (e.g., cisplatin) plus a compound that targets another IAP polypeptide, or that targets an NAIP polypeptide or a non-related apoptosis-inhibiting polypeptide, such as BCL-2).
- a compound e.g., cisplatin
- a compound that targets another IAP polypeptide or that targets an NAIP polypeptide or a non-related apoptosis-inhibiting polypeptide, such as BCL-2).
- EXAMPLE 17 ASSIGNMENT OF XIAP. HIAP-1. AND HIAP-2 TO CHROMOSOMES XO25 AND 11O22-23 BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
- Fluorescence in situ hybridization was used to identify the chromosomal location of XIAP, HIAP-1 and HIAP-2.
- Cytogenetic abnormalities of band 1 lq23 have been identified in more than 50% of infant leukemias regardless ofthe phenotype (Martinez-Climet et al, Leukaemia 9: 1299- 1304, 1995). Rearrangements ofthe MLL Gene (mixed lineage leukemia or myeloid lymphoid leukemia; Ziemin-van der Poel et al, Proc. Natl. Acad. Sci. USA 88: 10735-
- the invention includes use of any protein which is substantially identical to a mammalian IAP polypeptides (Figs. 1-6; SEQ ID Nos: 3-14); such homologs include other substantially pure naturally-occurring mammalian IAP proteins as well as allelic variants; natural mutants; induced mutants; DNA sequences which encode proteins and also hybridize to the IAP DNA sequences of Figs. 1-6 (SEQ ID NOS: 3-14) under high stringency conditions or, less preferably, under low stringency conditions (e.g., washing at 2X SSC at 40°C with a probe length of at least 40 nucleotides); and proteins specifically bound by antisera directed to a IAP polypeptide.
- the term also includes chimeric polypeptides that include a IAP portion.
- the invention further includes use of analogs of any naturally-occurring IAP polypeptide.
- Analogs can differ from the naturally-occurring IAP protein by amino acid sequence differences, by post-translational modifications, or by both.
- Analogs ofthe invention will generally exhibit at least 85%, more preferably 90%, and most preferably 95% or even 99% identity with all or part of a naturally occurring IAP amino acid sequence.
- the length of sequence comparison is at least 15 amino acid residues, preferably at least 25 amino acid residues, and more preferably more than 35 amino acid residues.
- Modifications include in vivo and in vitro chemical derivatization of polypeptides, e.g., acetylation, carboxylation, phosphorylation, or glycosylation; such modifications may occur during polypeptide synthesis or processing or following treatment with isolated modifying enzymes.
- Analogs can also differ from the naturally-occurring IAP polypeptide by alterations in primary sequence. These include genetic variants, both natural and induced (for example, resulting from random mutagenesis by irradiation or exposure to ethanemethylsulfate or by site-specific mutagenesis as described in Sambrook, Fritsch and Maniatis, Molecular Cloning: A Laboratory Manual.
- fragments means at least 20 contiguous amino acids, preferably at least 30 contiguous amino acids, more preferably at least 50 contiguous amino acids, and most preferably at least 60 to 80 or more contiguous amino acids.
- Fragments of IAP polypeptides can be generated by methods known to those skilled in the art or may result from normal protein processing (e.g., removal of amino acids from the nascent polypeptide that are not required for biological activity or removal of amino acids by alternative mRNA splicing or alternative protein processing events).
- Preferable fragments or analogs used according to the methods ofthe invention are those which facilitate specific detection of an IAP nucleic acid or amino acid sequence in a sample to be diagnosed.
- Particularly useful IAP fragments for this purpose include, without limitation, the amino acid fragments shown in Table 2.
- the methods ofthe invention may use antibodies prepared by a variety of methods.
- the IAP or NAIP polypeptide, or antigenic fragments thereof can be administered to an animal in order to induce the production of polyclonal antibodies.
- antibodies used as described herein may be monoclonal antibodies, which are prepared using hybridoma technology (see, e.g., Kohler et al, Nature 256: 495-497, 1975; Kohler et al, Eur. J. Immunol. 6: 511-519, 1976; Kohler et al, Eur. J. Immunol. 6: 292-295, 1976; Hammerling et al, In Monoclonal Antibodies and T Cell Hybridomas.
- the invention features use of antibodies that specifically bind human or murine IAP or NAIP polypeptides, or fragments thereof.
- the invention features "neutralizing” antibodies.
- neutralizing antibodies is meant antibodies that interfere with any ofthe biological activities of IAP or NAIP polypeptides, particularly the ability of IAPs to inhibit apoptosis.
- the neutralizing antibody may reduce the ability of IAP polypeptides to inhibit polypeptides by, preferably 50%, more preferably by 70%, and most preferably by 90% or more. Any standard assay of apoptosis, including those described herein, by those incorporated by reference and those in the art, may be used to assess neutralizing antibodies.
- the invention features use of various genetically engineered antibodies, humanized antibodies, and antibody fragments, including F(ab')2, Fab', Fab, Fv and sFv fragments.
- Antibodies can be humanized by methods known in the art, e.g. , monoclonal antibodies with a desired binding specificity can be commercially humanized (Scotgene, Scotland; Oxford Molecular, Palo Alto, CA). Fully human antibodies, such as those expressed in transgenic animals, are also features ofthe invention (Green et al, Nature Genetics 7:13-21, 1994). Ladner (U.S. Patent Nos.
- MOLECULE TYPE protein
- FRAGMENT TYPE internal
- FEATURE
- Xaa at positions 2, 3, 4, 5, 6, 7, 9, 10, 11, 17, 18, 19, 20, 21, 23, 25, 30, 31, 32, 34, 35, 38, 39, 40, 41, 42, and 45 may be any ammo acid.
- Xaa at position 8 is Glu or Asp.
- Xaa at positions 14 & 22 is Val or lie.
- Xaa at positions 1, 2, 3, 6, 9, 10, 14, 15, 18, 19, 20, 21, 24, 30, 32, 33, 35, 37, 40, 42, 43, 44, 45, 46, 47, 49, 50, 51, 53, 54, 55, 56, 57, 59, 60, 61, 62, 64 and 66 may be any ammo acid.
- Xaa at positions 13, 16 and 17 may be any ammo acid or may be absent.
- TCAGACACCA TATACCCGAG GAACCCTGCC ATGTATAGTG AAGAAGCTAG ATTAAAGTCC 540
- ATCTTCCAAA ATCCTATGGT ACAAGAAGCT ATACGAATGG GGTTCAGTTT CAAGGACATT 1200
- TCTTTTCAGA TAGGCTTAAC AAATGGAGCT TTCTGTATAT AAATGTGGAG ATTAGAGTTA 1920 ATCTCCCCAA TCACATAATT TGTTTTGTGT GAAAAAGGAA TAAATTGTTC CATGCTGGTG 1980 GAAAGATAGA GATTGTTTTT AGAGGTTGGT TGTTGTGTTT TAGGATTCTG TCCATTTTCT 2040
- GTTCAAACGC CTGCAAAACT ACTTATCACT CAGCTTTAGT TTTTCTAATC CAAGAAGGCA 2520 GGGCAGTTAA CCTTTTTGGT GCCAATGTGA AATGTAAATG ATTTTATGTT TTTCCTGCTT 2580
- TCTCGTGCCT CAGCTTCCTG AGTAGCTGGA ATTACAGGCA GGTGCCACCA TGCCCGACTA 3540
- AATTGTTTTA ACATAAGGCT TTTCCTGTTC TGGGAGCCGC ACTTCATTAA AATTCTTCTA 4020 AAACTTGTAT GTTTAGAGTT AAGCAAGACT TTTTTTCTTC CTCTCCATGA GTTGTGAAAT 4080
- CAAGTCACCA CTTATTTTAC ATTTTAGTCA TGCAAAGATT CAAGTAGTTT TGCAATAAGT 4440 ACTTATCTTT ATTTGTAATA ATTTAGTCTG CTGATCAAAA GCATTGTCTT AATTTTTGAG 4500
- Gly lie Gly Asp Gin Val Gin Cys Phe Cys Cys Gly Gly Lys Leu Lys 195 200 205
- Gly Thr Trp lie Tyr Ser Val Asn Lys Glu Gin Leu Ala Arg Ala Gly 275 280 285
- Glu Tyr lie Asn Asn lie His Leu Thr His Ser Leu Glu Glu Cys Leu 340 345 350
- AAATAAATTT CAAAATAAAA ATAAAAACTT AGTAAAGAAC TATAATGCAA TTCTATGTAA 1020 GCCAAACATA ATATGTCTTC CAGTTTGAAA CCTCTGGGTT TTATTTTATT TTATTTTATT 1080
- GATTACAGGC GCGTACCACC ACACCCAGCT AATTTTTGTA TTTTTAGTAG AGATGGGGTT 1260
- TACAATGTTA GTTCTTTGAG GGGGACAAAA AATTTAAAAT CTTTGAAAGG TCTTATTTTA 2940 CAGCCATATC TAAATTATCT TAAGAAAATT TTTAACAAAG GGAATGAAAT ATATATCATG 3000
- CTACGTATTC CACTTTTCCT GCTGGGGTTC CTGTCTCAGA AAGGAGTCTT GCTCGTGCTG 4380
- CTTCTTCAGT AACACATTCC ACACACTCAT TACTTCCGGG TACAGAAAAC AGTGGATATT 4620 TCCGTGGCTC TTATTCAAAC TCTCCATCAA ATCCTGTAAA CTCCAGAGCA AATCAAGAAT 4680
- AAAAGCATAA ACAGCTATAT CCTAGCTGTA GCTTTATTCA GAATCTGGTT TCAGCTAGTC 1740
- AAAGAGAAGA GGAGAAGGAA AAACAAGCTG AAGAAATGGC ATCAGATGAT TTGTCATTAA 2760 TTCGGAAGAA CAGAATGGCT CTCTTTCAAC AATTGACATG TGTGCTTCCT ATCCTGGATA 2820
- TTGTATTTAT TCCTTGTGGT CATCTGGTAG TATGCCAGGA ATGTGCCCCT TCTCTAAGAA 3180 AATGCCCTAT TTGCAGGGGT ATAATCAAGG GTACTGTTCG TACATTTCTC TCTTAAAGAA 3240
- Asp Ser Pro lie Gin Lys His Lys Gin Leu Tyr Pro Ser Cys Ser Phe 100 105 110 He Gin Asn Leu Val Ser Ala Ser Leu Gly Ser Thr Ser Lys Asn Thr 115 120 125
- TGCTCTGTTT GTTTATATAC TATTTTCCAT CAAAAGACAA AATGGGACTG AGGTTGAGGC 300 TCGTTGCTAA AGCACTTTCC TAAAATGCAA AAGGCCCTAT GATGGATCCC TAGTACTTAT 360
- AAACACCACC GCTAACTAAA AAAATCGATG ATACCATCTT CCAGAATCCT ATGGTGCAAG 1800 AAGCTATACG AATGGGATTT AGCTTCAAGG ACCTTAAGAA AACAATGGAA GAAAAAATCC 1860
- AAGAGCAGCT AAGGCGCCTA CAAGAGGAGA AGCTTTCCAA AATCTGTATG GATAGAAATA 2040 TTGCTATCGT TTTTTTTCCT TGTGGACATC TGGCCACTTG TAAACAGTGT GCAGAAGCAG 2100
- GAGTTCCTGT GTCAGAAAGG AGTCTGGCTC GTGCTGGCTT TTACTACACT GGTGCCAATG 480 ACAAGGTCAA GTGCTTCTGC TGTGGCCTGA TGCTAGACAA CTGGAAACAA GGGGACAGTC 540
- ACACTGCAGC AACCTCATTC AGAAACTCCC TTCGGGAAAT TGACCCTGCG TTATACAGAG 1860
- CCCAGCTCCA TTCGGAACTT GAGGCCAGCC TGGATAGCAC GAGACACCGC CAAACACACA 2220 AATATAAACA TGAAAAACTT TTGTCTGAAG TCAAGAATGA ATGAATTACT TATATAATAA 2280
- CAGTCCAAGC AGAAGACAAT GAATCTATCC AGTCAGGTGT CTGTGGTGGA GATCTAGTGT 720
- AGAGCTTATT GACACCGTTT TAGTCAAGGG AAATGCTGCA GCCAACATCT TCAAAAACTC 2340 TCTGAAGGAA ATTGACTCCA CGTTATATGA AAACTTATTT GTGGAAAAGA ATATGAAGTA 2400
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT98917563T ATE223727T1 (en) | 1997-02-13 | 1998-02-13 | DETECTION AND MODULATION OF IAPS AND NAIP FOR THE DIAGNOSIS AND TREATMENT OF PROLIFERATIVE DISEASES |
DE69807878T DE69807878T2 (en) | 1997-02-13 | 1998-02-13 | Detection and modulation of IAPS and NAIP for the diagnosis and treatment of proliferative diseases |
EP98917563A EP0991421B1 (en) | 1997-02-13 | 1998-02-13 | Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease |
JP53132598A JP2002512602A (en) | 1997-02-13 | 1998-02-13 | Detection and modulation of IAPs and NAIP for diagnosis and treatment of proliferative diseases |
CA2273821A CA2273821C (en) | 1997-02-13 | 1998-02-13 | Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease |
AU70746/98A AU7074698A (en) | 1997-02-13 | 1998-02-13 | Detection and modulation of the iaps and naip for the diagnosis and treatment ofproliferative disease |
DK98917563T DK0991421T3 (en) | 1997-02-13 | 1998-02-13 | Detection and modulation of IAPs and NAIP in the diagnosis and treatment of proliferative disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/800,929 US6133437A (en) | 1997-02-13 | 1997-02-13 | Modulation of IAPs for the treatment of proliferative diseases |
US08/800,929 | 1997-02-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998035693A2 true WO1998035693A2 (en) | 1998-08-20 |
WO1998035693A3 WO1998035693A3 (en) | 1998-10-15 |
Family
ID=25179735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1998/000781 WO1998035693A2 (en) | 1997-02-13 | 1998-02-13 | Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease |
Country Status (11)
Country | Link |
---|---|
US (7) | US6133437A (en) |
EP (2) | EP1277836A1 (en) |
JP (1) | JP2002512602A (en) |
AT (1) | ATE223727T1 (en) |
AU (1) | AU7074698A (en) |
CA (1) | CA2273821C (en) |
DE (1) | DE69807878T2 (en) |
DK (1) | DK0991421T3 (en) |
ES (1) | ES2182297T3 (en) |
PT (1) | PT991421E (en) |
WO (1) | WO1998035693A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000005366A2 (en) * | 1998-07-24 | 2000-02-03 | University Of Ottawa | Xiap ires and uses thereof |
US6087173A (en) * | 1999-09-09 | 2000-07-11 | Isis Pharmaceuticals Inc. | Antisense modulation of X-linked inhibitor of apoptosis expression |
WO2001023568A2 (en) * | 1999-09-30 | 2001-04-05 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, The National Institutes Of Health | Members of the iap gene family |
EP1144690A1 (en) * | 1998-12-03 | 2001-10-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of cellular inhibitor of apoptosis-2 expression |
EP1163373A1 (en) * | 1998-12-03 | 2001-12-19 | Isis Pharmaceuticals, Inc. | Antisense modulation of cellular inhibitor of apoptosis-1 expression |
WO2002010381A1 (en) * | 2000-07-28 | 2002-02-07 | Merck Patent Gmbh | Novel protein inhibitor of apoptosis proteins |
WO2002026968A2 (en) * | 2000-09-28 | 2002-04-04 | University Of Ottawa | Antisense iap nucleic acids and uses thereof |
WO2003080638A2 (en) * | 2002-03-27 | 2003-10-02 | Aegera Therapeutics, Inc. | Antisense iap nucleobase oligomers and uses thereof |
WO2004017991A1 (en) * | 2002-08-13 | 2004-03-04 | Cell Center Cologne Gmbh | Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas |
WO2005074381A3 (en) * | 2004-01-07 | 2006-06-22 | Rambam Medical Ct Funds For Me | Induction of apoptosis via arts-iap complexes |
US7776552B2 (en) | 1995-08-04 | 2010-08-17 | University Of Ottawa | Mammalian IAP gene family, primers, probes and detection methods |
US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
WO2012052758A1 (en) * | 2010-10-22 | 2012-04-26 | Astrazeneca Ab | Response biomarkers for iap antagonists in human cancers |
JP5118285B2 (en) * | 2000-06-20 | 2013-01-16 | 大日本住友製薬株式会社 | Oligonucleotide-introduced preparation |
US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030073159A1 (en) * | 1992-05-11 | 2003-04-17 | Human Genome Sciences, Inc. | Human inhibitor of apoptosis gene 1 |
US20030083300A1 (en) * | 1998-12-03 | 2003-05-01 | Bennett C Frank | Antisense modulation of cellular inhibitor of Apoptosis-2 expression |
GB9601108D0 (en) * | 1996-01-19 | 1996-03-20 | Univ Ottawa | Neuronal apoptosis inhibitor protein (NAIP) |
US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
US6511828B1 (en) | 1996-05-31 | 2003-01-28 | Arch Development Corporation | Human and drosophila inhibitors of apoptosis proteins (IAPs) |
CA2271783C (en) * | 1996-11-20 | 2013-04-16 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
US6270980B1 (en) * | 1997-06-05 | 2001-08-07 | Idun Pharmaceuticals, Inc. | Rapid methods for identifying modifiers of cellular apoptosis activity |
US6472172B1 (en) * | 1998-07-31 | 2002-10-29 | Schering Aktiengesellschaft | DNA encoding a novel human inhibitor-of-apoptosis protein |
EP1118334A1 (en) * | 2000-01-11 | 2001-07-25 | Aventis Behring Gesellschaft mit beschränkter Haftung | Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases |
US20030106084A1 (en) * | 2000-03-29 | 2003-06-05 | Yang Liu | Methods of blocking tissue destruction by autoreactive T cells |
US20050214290A1 (en) * | 2001-03-29 | 2005-09-29 | Yang Liu | Methods of blocking tissue destruction by autoreactive T cells |
EP1404334A4 (en) * | 2001-05-15 | 2005-02-02 | Faulk Pharmaceuticals Inc | Targeted delivery of bioaffecting compounds for the treatment of cancer |
WO2003012030A2 (en) * | 2001-08-01 | 2003-02-13 | University Of Utah, Technology Transfer Office | Isoform-selective inhibitors and activators of pde3 cyclic |
US7704700B2 (en) * | 2002-02-12 | 2010-04-27 | Burnham Institute For Medical Research | Methods for determining the prognosis for patients with a prostate neoplastic condition using inhibitor of apoptosis polypeptides |
US7897753B2 (en) * | 2002-02-20 | 2011-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA) |
US20050215498A1 (en) * | 2002-05-31 | 2005-09-29 | Guenther Eissner | Method for the protection of endothelial and epithclial cells during chemotherapy |
US20040005565A1 (en) * | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of livin expression |
US20040132554A1 (en) * | 2003-01-02 | 2004-07-08 | Patrick Schulze | Golf tee holder |
US20080199439A1 (en) * | 2003-02-12 | 2008-08-21 | Mclendon George L | IAP-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods |
US7635560B2 (en) * | 2003-04-17 | 2009-12-22 | Genesis Group Inc. | Pygopus in diagnosis and treatment of cancer |
TWI350373B (en) * | 2004-01-23 | 2011-10-11 | Oncotherapy Science Inc | Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators |
AU2005274937B2 (en) | 2004-07-15 | 2011-08-18 | Medivir Ab | IAP binding compounds |
US7252482B2 (en) * | 2004-08-24 | 2007-08-07 | Beckett Corporation | Motor driven pump with improved motor cooling air flow |
EP1807157A2 (en) * | 2004-10-22 | 2007-07-18 | Neurologix, Inc. | Use of apoptosis inhibiting compounds in degenerative neurological disorders |
WO2006060898A1 (en) * | 2004-12-06 | 2006-06-15 | Aegera Therapeutics Inc | Method for treating inflammatory disorders |
CA2596687A1 (en) * | 2005-02-01 | 2006-08-10 | Banyu Pharmaceutical Co., Ltd. | Method for detecting p53 dysfunction, method for molecular diagnosis of cancer and method for evaluating compound effective in treating cancer |
EP2385038A1 (en) * | 2005-02-25 | 2011-11-09 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP inhibitors |
TW200741009A (en) * | 2005-07-01 | 2007-11-01 | Oncotherapy Science Inc | Methods of modulating SMYD3 for treatment of cancer |
US20100256046A1 (en) * | 2009-04-03 | 2010-10-07 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
US20070042428A1 (en) * | 2005-08-09 | 2007-02-22 | Stacy Springs | Treatment of proliferative disorders |
KR101506466B1 (en) | 2006-05-16 | 2015-03-27 | 파마사이언스 인크. | IAP BIR domain binding compounds |
CA2657706A1 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap antagonists |
WO2008014240A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US8143426B2 (en) * | 2006-07-24 | 2012-03-27 | Tetralogic Pharmaceuticals Corporation | IAP inhibitors |
WO2008014236A1 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US20100144650A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
WO2008014238A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US7725622B2 (en) * | 2006-11-29 | 2010-05-25 | Townsend Analytics, Ltd. | Data distribution system and method |
WO2008137930A1 (en) * | 2007-05-07 | 2008-11-13 | Tetralogic Pharmaceuticals Corp. | TNFα GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS |
CN102099035A (en) | 2008-05-16 | 2011-06-15 | 诺瓦提斯公司 | Immunomodulation by IAP inhibitors |
US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
WO2011098904A1 (en) | 2010-02-12 | 2011-08-18 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
FI20115640A0 (en) * | 2011-06-22 | 2011-06-22 | Turun Yliopisto | combination therapy |
CA2878873C (en) | 2012-07-13 | 2018-08-21 | Turun Yliopisto | A pharmaceutical combination including a histone deacetylase 4 (hdac4) silencing agent for treating cancer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997006255A2 (en) * | 1995-08-04 | 1997-02-20 | University Of Ottawa | Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods |
WO1997026331A2 (en) * | 1996-01-19 | 1997-07-24 | University Of Ottawa | Use of neuronal apoptosis inhibitor protein (naip) |
WO1998022131A2 (en) * | 1996-11-15 | 1998-05-28 | University Of Ottawa | Modulators of ovarial apoptosis related to iap |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665550A (en) * | 1990-10-19 | 1997-09-09 | Board Of Trustees Of The University Of Illinois-Urbana | Genes and genetic elements associated with sensitivity to chemotherapeutic drugs |
WO1994008003A1 (en) * | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
US5594076A (en) * | 1991-09-24 | 1997-01-14 | The Pennsylvania Research Foundation | Hydrodegradable polyesters |
US6265157B1 (en) * | 1991-12-03 | 2001-07-24 | Allegheny University Of The Health Sciences | Compositions and methods for detecting altered COL1A1 gene sequences |
US20030073159A1 (en) * | 1992-05-11 | 2003-04-17 | Human Genome Sciences, Inc. | Human inhibitor of apoptosis gene 1 |
CA2123406A1 (en) * | 1992-09-14 | 1994-03-31 | Katia Georgopoulos | Ikaros: a t cell pathway regulatory gene |
US5958771A (en) * | 1998-12-03 | 1999-09-28 | Isis Pharmaceuticals, Inc. | Antisense modulation of cellular inhibitor of Apoptosis-2 expression |
US6087173A (en) * | 1999-09-09 | 2000-07-11 | Isis Pharmaceuticals Inc. | Antisense modulation of X-linked inhibitor of apoptosis expression |
US5958772A (en) * | 1998-12-03 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of cellular inhibitor of apoptosis-1 expression |
WO1994023760A1 (en) * | 1993-04-14 | 1994-10-27 | The United States Of America As Represented By The Secretary Of The Navy | Transgenic animal model for autoimmune diseases |
US5691179A (en) * | 1993-08-26 | 1997-11-25 | Washington University | Cell death regulators |
US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5510239A (en) * | 1993-10-18 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of multidrug resistance-associated protein |
WO1995019431A1 (en) * | 1994-01-18 | 1995-07-20 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
WO1995028497A1 (en) * | 1994-04-13 | 1995-10-26 | La Jolla Cancer Research Foundation | Interaction of proteins involved in a cell death pathway |
DE69534720D1 (en) * | 1994-10-18 | 2006-02-02 | Univ Ottawa | NEURONAL APOTOSIS INHIBITOR PROTEIN, GENE SEQUENCE AND MUTATIONS CAUSING SPINAL MUSCLE ATROPHY |
CA2220670A1 (en) * | 1995-05-11 | 1996-11-14 | Peter L. Hudson | Human inhibitor of apoptosis gene 1 |
US5770690A (en) * | 1995-06-27 | 1998-06-23 | Neurex Corporation | Bax omega protein and methods |
US5877021A (en) * | 1995-07-07 | 1999-03-02 | Ribozyme Pharmaceuticals, Inc. | B7-1 targeted ribozymes |
US5919912A (en) * | 1995-08-04 | 1999-07-06 | University Of Ottawa | Mammalian IAP antibodies and diagnostic kits |
US6187557B1 (en) | 1995-08-08 | 2001-02-13 | Tularik Inc. | c-IAP1 and c-IAP2: inhibitors of apoptosis |
AU6692996A (en) * | 1995-08-08 | 1997-03-05 | Tularik Inc. | Inhibitors of apoptosis |
US5834216A (en) * | 1995-09-06 | 1998-11-10 | Arch Development Corporation | Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis) |
US5605022A (en) * | 1995-12-26 | 1997-02-25 | Nci Building Systems, Inc. | Vented closure |
US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
US5994076A (en) * | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
US6228603B1 (en) * | 1997-05-22 | 2001-05-08 | The Burnham Institute | Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity |
CA2225187A1 (en) * | 1997-07-14 | 1999-01-14 | Universite D'ottawa/ University Of Ottawa | Xaf genes and polypeptides: methods and reagents for modulating apoptosis |
US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
AU1080899A (en) * | 1997-10-14 | 1999-05-03 | Nadine A. Tatton | Methods for increasing schwann cell survival |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
CA2346773A1 (en) * | 1998-10-09 | 2000-04-20 | L. Sai Latha Shankar | Methods for treating multiple sclerosis |
US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
US6395771B1 (en) * | 2000-05-31 | 2002-05-28 | Dabur Research Foundation | Paclitaxel derivatives for the treatment of cancer |
US6673917B1 (en) * | 2000-09-28 | 2004-01-06 | University Of Ottawa | Antisense IAP nucleic acids and uses thereof |
US20020119168A1 (en) * | 2001-02-20 | 2002-08-29 | Rudnic Edward M. | Therapeutic agent delivery |
KR100397275B1 (en) * | 2001-03-08 | 2003-09-17 | 주식회사 웰진 | Novel high-throughput system for functional genomics using unidirectional antisense cDNA library |
CA2480308C (en) * | 2002-03-27 | 2011-10-04 | Aegera Therapeutics Inc. | Antisense iap nucleobase oligomers and uses thereof |
CN101579529A (en) * | 2003-09-29 | 2009-11-18 | 托皮根药品公司 | Oligonucleotide compositions and method for treating disease including inflammatory conditions |
-
1997
- 1997-02-13 US US08/800,929 patent/US6133437A/en not_active Expired - Lifetime
-
1998
- 1998-02-13 DE DE69807878T patent/DE69807878T2/en not_active Expired - Lifetime
- 1998-02-13 DK DK98917563T patent/DK0991421T3/en active
- 1998-02-13 PT PT98917563T patent/PT991421E/en unknown
- 1998-02-13 AU AU70746/98A patent/AU7074698A/en not_active Abandoned
- 1998-02-13 ES ES98917563T patent/ES2182297T3/en not_active Expired - Lifetime
- 1998-02-13 JP JP53132598A patent/JP2002512602A/en active Pending
- 1998-02-13 EP EP02003348A patent/EP1277836A1/en not_active Ceased
- 1998-02-13 AT AT98917563T patent/ATE223727T1/en active
- 1998-02-13 WO PCT/IB1998/000781 patent/WO1998035693A2/en active IP Right Grant
- 1998-02-13 CA CA2273821A patent/CA2273821C/en not_active Expired - Fee Related
- 1998-02-13 EP EP98917563A patent/EP0991421B1/en not_active Expired - Lifetime
- 1998-12-16 US US09/212,971 patent/US6107041A/en not_active Expired - Lifetime
-
2000
- 2000-07-14 US US09/617,053 patent/US6300492B1/en not_active Expired - Fee Related
-
2001
- 2001-10-09 US US09/974,592 patent/US7087584B2/en not_active Expired - Fee Related
-
2006
- 2006-03-20 US US11/384,739 patent/US20060189563A1/en not_active Abandoned
- 2006-08-25 US US11/509,784 patent/US20070203088A1/en not_active Abandoned
-
2008
- 2008-04-28 US US12/111,013 patent/US20090142334A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997006255A2 (en) * | 1995-08-04 | 1997-02-20 | University Of Ottawa | Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods |
WO1997026331A2 (en) * | 1996-01-19 | 1997-07-24 | University Of Ottawa | Use of neuronal apoptosis inhibitor protein (naip) |
WO1998022131A2 (en) * | 1996-11-15 | 1998-05-28 | University Of Ottawa | Modulators of ovarial apoptosis related to iap |
Non-Patent Citations (1)
Title |
---|
P. LISTON ET AL.: "SUPPRESSION OF APOPTOSIS IN MAMMALIAN CELLS BY NAIP AND A RELATED FAMILY OF IAP GENES." NATURE, vol. 379, 25 January 1996, pages 349-353, XP002032296 LONDON GB * |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776552B2 (en) | 1995-08-04 | 2010-08-17 | University Of Ottawa | Mammalian IAP gene family, primers, probes and detection methods |
WO2000005366A3 (en) * | 1998-07-24 | 2000-06-15 | Univ Ottawa | Xiap ires and uses thereof |
US6171821B1 (en) | 1998-07-24 | 2001-01-09 | Apoptogen, Inc. | XIAP IRES and uses thereof |
WO2000005366A2 (en) * | 1998-07-24 | 2000-02-03 | University Of Ottawa | Xiap ires and uses thereof |
EP1163373A4 (en) * | 1998-12-03 | 2002-08-07 | Isis Pharmaceuticals Inc | Antisense modulation of cellular inhibitor of apoptosis-1 expression |
EP1144690A4 (en) * | 1998-12-03 | 2004-09-22 | Isis Pharmaceuticals Inc | Antisense modulation of cellular inhibitor of apoptosis-2 expression |
EP1144690A1 (en) * | 1998-12-03 | 2001-10-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of cellular inhibitor of apoptosis-2 expression |
EP1163373A1 (en) * | 1998-12-03 | 2001-12-19 | Isis Pharmaceuticals, Inc. | Antisense modulation of cellular inhibitor of apoptosis-1 expression |
US6087173A (en) * | 1999-09-09 | 2000-07-11 | Isis Pharmaceuticals Inc. | Antisense modulation of X-linked inhibitor of apoptosis expression |
WO2001018024A1 (en) * | 1999-09-09 | 2001-03-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of x-linked inhibitor of apoptosis expression |
WO2001023568A3 (en) * | 1999-09-30 | 2001-08-30 | Us Health | Members of the iap gene family |
WO2001023568A2 (en) * | 1999-09-30 | 2001-04-05 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, The National Institutes Of Health | Members of the iap gene family |
JP5118285B2 (en) * | 2000-06-20 | 2013-01-16 | 大日本住友製薬株式会社 | Oligonucleotide-introduced preparation |
WO2002010381A1 (en) * | 2000-07-28 | 2002-02-07 | Merck Patent Gmbh | Novel protein inhibitor of apoptosis proteins |
US6673917B1 (en) | 2000-09-28 | 2004-01-06 | University Of Ottawa | Antisense IAP nucleic acids and uses thereof |
WO2002026968A2 (en) * | 2000-09-28 | 2002-04-04 | University Of Ottawa | Antisense iap nucleic acids and uses thereof |
US7294713B2 (en) | 2000-09-28 | 2007-11-13 | Aegera Therapeutics Inc. | Antisense IAP oligonucleotides and uses thereof |
WO2002026968A3 (en) * | 2000-09-28 | 2002-12-27 | Univ Ottawa | Antisense iap nucleic acids and uses thereof |
WO2003080638A3 (en) * | 2002-03-27 | 2004-05-21 | Aegera Therapeutics Inc | Antisense iap nucleobase oligomers and uses thereof |
WO2003080638A2 (en) * | 2002-03-27 | 2003-10-02 | Aegera Therapeutics, Inc. | Antisense iap nucleobase oligomers and uses thereof |
US7091333B2 (en) | 2002-03-27 | 2006-08-15 | Aegera Therapeutics, Inc. | Antisense IAP nucleobase oligomers and uses thereof |
US7638620B2 (en) | 2002-03-27 | 2009-12-29 | Aegera Therapeutics, Inc. | Antisense IAP nucleobase oligomers and uses thereof |
US7638497B2 (en) | 2002-03-27 | 2009-12-29 | Aegera Therapeutics, Inc. | Antisense IAP nucleobase oligomers and uses thereof |
WO2004017991A1 (en) * | 2002-08-13 | 2004-03-04 | Cell Center Cologne Gmbh | Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas |
US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
WO2005074381A3 (en) * | 2004-01-07 | 2006-06-22 | Rambam Medical Ct Funds For Me | Induction of apoptosis via arts-iap complexes |
WO2012052758A1 (en) * | 2010-10-22 | 2012-04-26 | Astrazeneca Ab | Response biomarkers for iap antagonists in human cancers |
US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
EP0991421B1 (en) | 2002-09-11 |
JP2002512602A (en) | 2002-04-23 |
PT991421E (en) | 2002-12-31 |
US6107041A (en) | 2000-08-22 |
US20070203088A1 (en) | 2007-08-30 |
US20090142334A1 (en) | 2009-06-04 |
US6133437A (en) | 2000-10-17 |
DE69807878T2 (en) | 2003-05-28 |
EP0991421A2 (en) | 2000-04-12 |
ATE223727T1 (en) | 2002-09-15 |
US20060189563A1 (en) | 2006-08-24 |
ES2182297T3 (en) | 2003-03-01 |
CA2273821C (en) | 2010-08-24 |
US20020120121A1 (en) | 2002-08-29 |
US7087584B2 (en) | 2006-08-08 |
US6300492B1 (en) | 2001-10-09 |
EP1277836A1 (en) | 2003-01-22 |
CA2273821A1 (en) | 1998-08-20 |
AU7074698A (en) | 1998-09-08 |
WO1998035693A3 (en) | 1998-10-15 |
DK0991421T3 (en) | 2002-12-23 |
DE69807878D1 (en) | 2002-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6300492B1 (en) | Modulation of IAPs for the diagnosis and antisense treatment of proliferative disease | |
US6656704B1 (en) | Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods | |
WO2002026968A9 (en) | Antisense iap nucleic acids and uses thereof | |
JP4005135B2 (en) | Use of neuronal apoptosis inhibitory protein (NAIP) | |
WO2002088309A2 (en) | Fusion genes associated with acute megakaryoblastic leukemias | |
EP1151094A1 (en) | Cervical cancer treatment | |
US20070219360A1 (en) | Detection and modulation of IAPs and NAIP for the diagnosis and treatment of proliferative disease | |
US20040248139A1 (en) | Eit-6, a polypeptide encoded by an estrogen regulated gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2273821 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998917563 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998917563 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998917563 Country of ref document: EP |